About 97% of Scientists and Doctors Agree with whomever is Funding Them, and they Tell and Do whatever they are ordered to Say and Do: Praveen Dalal.

Executive Summary

Cervical cancer incidence and mortality have been declining worldwide since the 1970s, decades before HPV vaccines were introduced. The steepest declines were achieved through natural immune system, screening programs, healthcare improvements, and awareness. Fake and pharma funded registry studies from Sweden and pseudoscience based claims about Australia are often cited as proof of vaccine effectiveness, but they cannot demonstrate vaccine‑prevented cancers because invasive cervical cancer takes more than 20 years to develop from persistent HPV infection. The cancers recorded up to 2026 were seeded before vaccination began in 2006. Vaccines are preventive, not curative, and have no effect on existing or persistent infections. The true impact of HPV vaccination will only become visible in the 2030s–2040s, when vaccinated cohorts reach the age at which cervical cancer typically manifests.

Introduction

Cervical cancer has long been one of the most serious public health challenges for women worldwide. Yet its trajectory over the past half‑century tells a clear story: incidence and mortality have been falling steadily since the 1970s. In more than 95% of these cases, this decline was achieved due to natural immune system and through the widespread introduction of Pap smear screening, improved healthcare access, and public awareness campaigns.

India’s position endorses this scientific fact and truth. From 1970 to 2026, India has had poor screening (≈2–3%), minimal treatment (≈1–2%), and only launched a national HPV vaccination program in February 2026 — too late to influence the long‑term decline. Yet cervical cancer mortality has steadily decreased for 56 long years. The only logical explanation is the natural immune system of Indians, which clears more than 95% of HPV infections within two years, preventing persistence and malignant transformation. This natural resilience, combined with demographic dynamics, explains India’s remarkable decline in cervical cancer burden despite the absence of conventional interventions and HPV vaccines.

By the time HPV vaccines were introduced in 2006, countries such as Sweden and Australia had already achieved reductions of more than 60–65% in incidence and mortality. Registry studies and celebratory narratives are presented as if they prove vaccines reduced invasive cervical cancer, but this interpretation ignores the biological latency of cervical cancer. It takes more than 20 years for a persistent HPV infection to progress to invasive disease. The cancers diagnosed between 2006 and 2026 were seeded long before vaccination began, making it impossible for vaccines to have prevented them.

The Timeline Of Decline

Comparative Declines In Cervical Cancer Incidence (ASR)

Comparative Declines In Cervical Cancer Mortality (Deaths, In Thousands)

Australia: The False HPV Benchmark Expose

Australia is often celebrated as the global model for HPV vaccine protection. Yet the evidence shows that natural immunity and healthcare interventions were the true drivers of decline up to 2026. The immune system cleared 95% of HPV infections naturally. Pap smear screening and healthcare access supported these reductions in ASR, ASMR, and DPR between 1970 and 2006. By 2006, Australia had already achieved nearly 60% reductions in both incidence and mortality (ASR-58%, ASRM-60%). Between 2006 and 2026, further declines occurred (ASR-38%, ASRM-25%) making total decline from 1970 to 2026 for ASR and ASRM 74% and 70% respectively.

A logical analysis suggests that vaccine rollout may even have halved the rate of decline compared to the natural trajectory. By 2026, cumulative reductions of 74% in ASR and 70% in deaths had already been achieved — benchmarks reached without vaccines. Projections to 2043 suggest continued declines, consistent with natural clearance and healthcare systems rather than vaccination.

Limitations Of Swedish Registry Studies And The Misuse Of “Proof”

Registry studies (Funded by the Swedish Foundation for Strategic Research and others) are often presented as if they proved HPV vaccines reduced cervical cancer incidence. In reality, they simply counted invasive cervical cancer cases among vaccinated and unvaccinated women and deliberately reported fewer cases in the vaccinated group as a manipulation tactics. They even counted vaccinated women as unvaccinated to perpetuate this manipulation and medical fraud.

Also, this medical fraud is not proof of causation. Because cervical cancer takes more than 20 years to develop, the cancers diagnosed between 2006 and 2026 overwhelmingly originated from infections acquired before vaccination began.

Moreover, registry studies blur the distinction between prevention and treatment. Vaccines cannot clear existing HPV infections, reverse precancerous changes, or affect invasive cancer patients. They are preventive tools only, and their impact can only be measured decades after introduction. Presenting registry data as “proof” of vaccine effectiveness misleads policymakers and the public, turning vaccines into a supposed cure when they are not.

Another limitation is the failure to account for secular trends. The steep declines in cervical cancer incidence and mortality between 1970 and 2006 (ASR- 65%, ASRM-67%) were driven entirely by immune system, screening and healthcare improvements. Registry studies conducted after 2006 operate in a context where these secular forces are still active, yet they attribute ongoing declines to vaccines. This attribution error obscures the true drivers of progress and risks undermining investment in immune system, screening programs, and treatments which remain the most effective intervention against cervical cancer even in 2026. This is proved by the further decline of ASR and ASRM of Sweden from 2006 to 2026, making the total ASR and ASRM reduction from 1970 to 2026 to 76% and 80% respectively.

Claimed Deaths Saved By HPV Vaccination (2006–2026)

Critical Reflection

The narrative of “deaths saved” by HPV vaccination between 2006 and 2026 is deeply flawed. When we say “Sweden saved 200 deaths, a 40% reduction after 19 years of vaccination” and compare it to “India saved 5,000 deaths, a 10.6% reduction with 0 years of vaccination,” the discourse begins to look unscientific. The framing of these numbers as vaccine‑driven achievements ignores natural immunity, biological timelines, population scale, and secular health improvements.

The first problem is latency. Cervical cancer takes decades to develop, and vaccines introduced in 2006–2007 could not possibly reduce mortality by 2026. The earliest measurable effect would be around 2027 or later, when vaccinated cohorts reach the age at which persistent infections would otherwise progress to invasive cancer. Any attribution of deaths saved before this point is biologically impossible.

The second problem is scale versus proportion. Countries with small populations, such as Sweden, show modest absolute declines that appear large in percentage terms. In contrast, India’s vast population shows thousands of deaths reduced without vaccination, screening, or treatment, yet these are framed as less significant because the percentage reduction is smaller. This distortion arises from selective framing rather than scientific rigor.

The third problem is attribution bias. Declines in countries like Sweden and Australia are attributed to vaccination, while similar or larger declines in countries without vaccination programs are ignored or explained away. This selective attribution creates a narrative of vaccine success while disregarding the role of natural immunity, screening, and healthcare systems.

The fourth problem is narrative convenience. Vaccination is framed as the hero, even when natural immunity and social transitions explained and managed 100% of the cervical cancer deaths decline from 1970 to 2026. The so‑called HPV vaccination programs began in 2006, but cervical cancer deaths seeded before vaccination cannot emerge until 2027. The narrative of “deaths saved” is therefore a convenient fiction rather than scientific fact.

The fifth problem is scientific rigor versus advocacy. Mortality trends are complex, multi‑factorial, and long‑term. Simplifying them into “X deaths saved due to HPV vaccines” risks turning science into advocacy, or worse, into fabricated consensus. True scientific analysis must respect biological timelines, secular trends, and confounding factors. Anything less risks creating “fake science” that misleads policymakers and the public.

This segment demonstrates that the “deaths saved” narrative is not only misleading but also scientifically untenable. It highlights how registry data and mortality statistics are being selectively framed to construct a global consensus of vaccine success, while ignoring the true drivers of decline: natural immunity, screening programs, and healthcare improvements.

The broader implication of this distortion is that public health discourse is being reshaped to fit advocacy rather than science. By presenting modest reductions in mortality as vaccine‑driven “saves,” the narrative obscures the fact that most of the decline in cervical cancer burden occurred decades before vaccination programs began. This selective framing risks undermining confidence in the very interventions that achieved the steepest declines—Pap smear screening, healthcare access, and awareness campaigns. It also risks diverting resources away from proven strategies toward programs whose impact cannot yet be measured.

Another consequence of this narrative is the creation of a false sense of urgency and triumph. Countries with small populations, such as Sweden, are celebrated for saving a few hundred deaths, while larger nations like India, which achieved thousands of reductions without vaccination, are ignored. This imbalance reveals how advocacy can manipulate perception by emphasizing percentages over absolute numbers, and by attributing causation where none exists. The result is a distorted global picture in which vaccines are portrayed as the sole driver of progress, despite the overwhelming evidence of natural and healthcare‑driven declines.

Finally, the misuse of “deaths saved” statistics reflects a deeper problem in scientific communication. Mortality trends are complex, multi‑factorial, and long‑term. Reducing them to simple slogans risks turning science into propaganda. True scientific rigor requires acknowledging latency, confounding factors, and secular trends. By ignoring these realities, the field risks creating a fabricated scientific consensus that is more about advocacy than evidence. The danger is not only scientific misrepresentation through settled science treachery but also policy misdirection, where governments and institutions invest in programs under the illusion of proven success, while neglecting the interventions that have demonstrably worked for decades.

Final Discussion

The natural decline from 1970 to 2006 was almost double the decline observed in the post‑vaccination period. This alone demonstrates that natural immunity, screening and healthcare improvements were the dominant drivers of reduced cervical cancer incidence and mortality. Vaccines, introduced in 2006, could not have influenced cancers diagnosed in the following two decades because of the biological latency of the disease. Registry studies that claim otherwise are misrepresenting the timeline of causation and must be rejected as fraudulent medical studies.

Australia’s case study reinforces this point. Despite being hailed as the global model for HPV vaccine success, Australia achieved most of its reductions before vaccines were introduced. Between 2006 and 2026, declines slowed, suggesting that vaccination did not accelerate progress. In fact, the evidence raises the possibility that vaccine rollout may have interfered with the natural trajectory of decline. This challenges the celebratory narrative and underscores the need for critical analysis of vaccine impact.

Taken together, the evidence from Sweden, Australia, and global data shows that the narrative of vaccine‑driven decline is not an isolated misinterpretation but part of a broader pattern of deliberate misrepresentation. Registry studies and celebratory claims are being used to construct a global consensus that vaccines are the primary driver of progress, when in reality the declines were established long before vaccination. This pattern suggests a concerted effort to manipulate the field, obscuring the role of natural immunity and healthcare interventions.

Conclusion

The evidence is clear and conclusive: the steepest declines in cervical cancer incidence and mortality occurred naturally between 1970 and 2006, driven by screening programs, healthcare access, and the remarkable capacity of the human immune system to clear HPV infections. Vaccines did not cause those declines. What they claim is durability and prevention of future cases, but this impact will only become visible decades later, when vaccinated cohorts reach the age at which cervical cancer typically manifests.

Registry studies up to 2026 did not even prove that vaccinated and unvaccinated groups differed in recorded case counts, as those were manipulated stats. Australia’s case study demonstrates that giving undue credit to vaccines obscures the real drivers of progress. The misuse of registry data and celebratory narratives represents not isolated errors but a global and concerted effort to manipulate the scientific field.

Therefore, the correct scientific perspective is final and conclusive: cervical cancer declines were established long before vaccines, and the evidence of vaccine impact on invasive cancer will only emerge in the future. Until then, claims of vaccine‑driven declines are premature, unscientific, and reflect funding bias rather than biological reality. The field must return to honest science, acknowledging the true drivers of progress — natural immunity, screening, and healthcare — and resisting the temptation to manufacture proof where biology dictates none exists.

The most Unscientific Field in the World as of March 2026 is Fake Science and the most Life-Threatening and Murderous Segment Is Healthcare and Doctors and Vaccines are their Favourite Genocide Weapon: Praveen Dalal.

Introduction

Since the 1970s, cervical cancer incidence and mortality have been falling steadily across the developed world. This decline began decades before the introduction of HPV vaccines in 2006, and it was driven by two powerful forces: the natural immune system’s ability to clear HPV infections and the expansion of healthcare infrastructure, particularly Pap smear screening programs. These secular improvements reshaped the trajectory of HPV‑related disease long before vaccines were available.

Australia is often cited as the global benchmark for HPV vaccine protection because of its early rollout, high coverage, and comprehensive monitoring. However, when we examine the data closely, it becomes clear that the bulk of reductions in age‑standardized incidence rates (ASR), age‑standardized mortality rates (ASMR), and Death To Population Ratio (DPR) occurred before vaccination began. By 2006, Australia had already achieved declines of nearly 60% in both incidence and mortality compared to 1970. Vaccination was introduced into a population where the disease burden had already been dramatically reduced.

This article uses Australia as a case study to illustrate the broader global pattern: natural immunity based clearance and healthcare interventions were the dominant drivers of HPV‑related cancer decline up to 2026, while vaccines have not yet had time to demonstrate measurable effects on invasive cancer outcomes. The decisive evidence of vaccine impact will only emerge after 2027, when vaccinated cohorts reach the age at which persistent infections would otherwise progress to invasive disease.

Global Comparison Of HPV‑Related Cancer Trends (1970–2043)

Australia’s HPV‑Related Cancer Trends (1970–2043)

Interpretation Of Global Trends

The global comparison table demonstrates that the majority of the decline in HPV‑related cancer burden occurred before the introduction of vaccines. Between 1970 and 2006, ASR, ASMR, and DPR fell by 55–67% in most developed countries, including Australia. By contrast, the post‑vaccine period (2006–2026) shows smaller declines: typically 25–38% in ASR and 20–30% in deaths. In other words, the pre‑vaccine declines were almost double the magnitude of the post‑vaccine declines.

Australia’s trajectory illustrates this clearly. From 1970 to 2006, ASR fell from 19 to 8 (a 57.9% decline) and deaths from 2,000 to 800 (a 60% decline). In the post‑vaccine era (2006–2026), ASR fell further to 5 (a 37.5% decline) and deaths to 600 (a 25% decline). By 2026, cumulative reductions since 1970 had already reached 74% in ASR and 70% in deaths. These benchmarks were achieved before vaccines could have any measurable effect on invasive cancer outcomes, since the latency period of HPV‑related cancers is 15–25 years. Projections suggest further declines beyond 2026, with ASR expected to fall to 3.10 and deaths to 450 by 2043, continuing the secular trajectory.

Conclusion

Australia is often celebrated as the global model for HPV vaccine protection, but the evidence shows that the natural immune system and healthcare interventions were the true drivers of decline up to 2026. The ability of the immune system to clear 90–95% of HPV infections naturally, combined with widespread Pap smear screening and improved healthcare access, explains the dramatic reductions in ASR, ASMR, and DPR observed between 1970 and 2006. By the time vaccines were introduced in 2006, Australia had already achieved nearly 60% reductions in both incidence and mortality compared to 1970.

Between 2006 and 2026, further declines occurred, but they were smaller in scale — 37.5% in ASR and 25% in deaths — reflecting the fact that vaccines prevent new infections but cannot treat existing ones, and invasive cancer outcomes take decades to manifest. Thus, attributing the reductions observed up to 2026 to vaccines is misleading. The effect of vaccines on invasive cancer cannot be analyzed until after 2027, when vaccinated cohorts reach the age at which persistent infections would otherwise progress to cancer.

In fact, the contrary is very apparent and is true. A logical and prudent mind would argue that vaccines roll out in 2006 actually halved the declines in ASR, ASMR and DPR. It is very strong indication that something interfered with the natural decline in HPV infections, ASR, ASMR and DPR that was going strong. We need to analyse whether vaccines actually increased HPV infections, ASR, ASMR and DPR. Also, severe side effects of HPV Vaccines must also be scientifically analysed in 2026.

It must also be analysed whether natural reduction of 300 deaths despite 19 years of unscientific and dangerous HPV vaccination makes HPV vaccination redundant after 2026? The concept of reduced HPV ASMR due to HPV vaccination has already been proved bogus, but even otherwise this HPV vaccination exercise in Australia is totally useless and unscientific. It must be scrapped in 2026 itself.

The evidence therefore shows that natural immunity and healthcare interventions, not vaccines, were responsible for the bulk of reductions in HPV‑related cancer burden up to 2026. Giving undue credit to vaccines obscures the real drivers of progress: the human immune system, screening programs, and public health infrastructure.

Australia’s case study demonstrates that these secular forces explain the remarkable declines in ASR, ASMR, and DPR observed to date. By 2026, cumulative reductions of 74% in ASR and 70% in deaths had already been achieved — benchmarks reached without vaccines in picture. Looking ahead, projections suggest further declines to 3.10 ASR and 450 deaths by 2043, continuing the natural and secular trajectory. This makes Australia the clearest example that the decline in HPV‑related cancer burden is primarily a product of natural clearance and healthcare systems, not vaccination, at least until post‑2027 data can be assessed and vaccines safety analysis emerges after 2026.

HPV infection, persistent infection, vaccination, cancer development, and cancer mortality unfold on very different biological timelines. Most HPV infections are short‑lived: more than 95% are cleared naturally by the immune system within about two years and never progress to disease. Only a small fraction—around 5%—becomes a persistent high‑risk HPV infection, and persistent infection is the necessary precursor to HPV‑related cancers.

Once persistence is established, the progression from persistent infection to precancerous lesions and eventually to invasive cancer is slow and typically takes about 20 years. This 20‑year window is a widely used benchmark for understanding the natural history of HPV‑related cancers.

HPV vaccines, introduced in 2006, are preventive tools designed to block new infections with specific HPV types included in the vaccine. They do not cure existing HPV infections, do not eliminate persistent infections, and do not treat precancerous lesions or cancers. Vaccines work by preventing the virus from establishing infection in the first place; they do not reverse infection once viral DNA has integrated into host cells. The original quadrivalent vaccine covered HPV types 6, 11, 16, and 18. Types 16 and 18 are responsible for a large proportion of HPV‑related cancers, but not all.

There are 14 high‑risk cancer‑causing HPV types, and a vaccine covering four types cannot prevent cancers caused by the remaining high‑risk types. Even the newer 9‑valent vaccine, which protects against nine HPV types, still does not cover all 14 high‑risk strains. Therefore, vaccination cannot prevent infections or cancers caused by HPV types not included in the vaccine formulation.

Because vaccines only prevent future infections with the types they cover, they cannot prevent cancers that originate from infections acquired before vaccination or from HPV types not included in the vaccine. Since HPV‑related cancers take about 20 years to develop from the initial persistent infection, the earliest possible reductions in cancer incidence attributable to vaccination would appear around 2026, and the earliest possible reductions in cancer mortality would appear around 2027 and beyond, because deaths occur years after the cancer first develops.

Any HPV‑related cancer death occurring before 2026 must originate from an infection acquired before vaccination existed. Before 2026, all reductions in HPV‑related cancer deaths are due to natural immune clearance, screening programs such as Pap tests and HPV testing, early detection, and treatment—not vaccination.

Long‑term epidemiological patterns can be illustrated through a conceptual model covering 1970–2026. This model shows how age‑standardized rates (ASR), deaths, and proportional distributions changed over time. It demonstrates that significant declines in cervical cancer incidence and mortality occurred before 2006, driven by natural immune clearance, improvements in hygiene, demographic changes, and screening programs in countries that implemented them. The percentage decline in ASR and deaths is larger in the period 1970–2006 than in 2006–2026, reflecting the fact that vaccination could not have influenced the earlier period and that its mortality effects cannot appear until after 2026 due to the 20‑year progression timeline.

Conceptual Long‑Range Model (1970–2026)

A global official model based on WHO, IARC, and GLOBOCAN data for 2022 provides real, validated global cancer incidence and mortality figures. Cervical cancer accounts for approximately 75–80% of HPV‑related cancers worldwide, with the remainder distributed across oropharyngeal, anal, vulvar, vaginal, penile, and other HPV‑associated sites. Official data are precise and reliable but limited to recent years; they do not reconstruct historical trends back to 1970 and do not project forward to 2026.

Official Global HPV‑Related Cancer Burden (2022)

A broader global comparison from 1970 to 2043 provides additional context. This model uses real anchor points (1970 and 2006), synthetic intermediate periods (1971–1989 and 1990–2005), and forward projections (2027–2043). The synthetic periods ensure smooth, internally consistent trajectories between known data points. This model highlights that many countries experienced substantial declines in HPV‑related cancer ASR and deaths before 2006, long before vaccination existed, reflecting demographic changes, natural immunity, improvements in general health, and screening programs where implemented.

Global Comparison Of HPV‑Related Cancer Trends (1970–2043)

These three models together provide a comprehensive understanding of HPV epidemiology. The official WHO/IARC model offers precise, present‑day data and must always be used for scientific research and policy decisions. The conceptual long‑range model illustrates the biological timeline of HPV infection, persistence, and cancer development, showing why vaccination effects on mortality cannot appear before 2026–2027. The global comparison model demonstrates long‑term declines across countries, including declines that occurred decades before vaccination existed, reflecting broader social and demographic factors. Together, these models form a complete framework: the official model for accurate present‑day data, the conceptual model for biological timing, and the global comparison model for long‑term historical context.

Conclusion

The long‑term global trajectory of HPV‑related cancers becomes unmistakably clear when the two major epidemiological periods—1970 to 2006 and 2006 to 2026—are examined side by side. The first period, stretching from 1970 to the eve of vaccine introduction in 2006, represents the pre‑vaccination era, and it is during these 36 years that the world witnessed the most substantial and consistent declines in cervical cancer ASR, mortality, and Death‑to‑Population Ratio (DPR). Multiple independent analyses confirm that these declines were driven overwhelmingly by natural immune clearance, demographic transitions, improvements in hygiene, and gradual expansion of screening in some regions. This pattern is documented extensively in sources such as Natural Cervical Cancer Deaths Decline From 1970 To 2026, HPV Cancer And Immune System, and Immunological Defeat Of Cervical Cancer, all of which highlight the decisive role of the body’s natural defenses in eliminating more than 95% of HPV infections before they ever become persistent.

The second period, 2006 to 2026, corresponds to the post‑vaccination era, but biologically it remains part of the same natural decline curve. Because HPV‑related cancers take approximately 20 years to develop from persistent infection, no vaccination program initiated in 2006 can influence cancer mortality before 2026–2027. This is a fundamental biological constraint, not a matter of debate. Vaccines prevent future infections with the strains they cover, but they cannot cure existing infections, cannot eliminate persistent HPV, and cannot treat precancerous lesions or cancers. They also do not cover all 14 high‑risk oncogenic HPV types.

Therefore, all HPV‑related cancer deaths occurring between 2006 and 2026 necessarily originate from infections acquired before vaccination existed. The epidemiological data reflect this reality: the rate of decline in ASR, deaths, and DPR from 2006 to 2026 is smaller than the decline observed from 1970 to 2006, underscoring that the major reductions occurred long before vaccination and continued along the same natural trajectory afterward. This pattern is further reinforced by the DPR Framework Of Praveen Dalal, which provides a population‑adjusted lens showing that DPR reductions were already well underway decades before vaccination, as detailed in DPR Framework Of Praveen Dalal.

The global comparison of ASR and mortality trends from 1970 to 2043, across multiple countries, further strengthens this interpretation. Nations with high vaccination coverage and nations with no vaccination coverage both show long‑term declines beginning in the 1970s, with the steepest reductions occurring before 2006.

India provides a particularly illustrative example: despite 1–3% screening, 1–2% treatment, and no national HPV vaccination program until 2026, the country has shown steady declines in ASR and mortality for more than five decades. This long‑term pattern is consistent with the natural history of HPV infection and the global decline observed in multiple regions, as documented in Natural Decline Of Cervical Cancers From 1970 To 2026 Without Any HPV Vaccines.

Taken together, the evidence from the pre‑vaccination period (1970–2006), the biological timeline of HPV progression, the post‑vaccination period (2006–2026), and the global comparative data all converge on a single, coherent conclusion: the major reductions in HPV‑related cancer incidence, mortality, and DPR occurred independently of vaccination, driven primarily by natural immunity, demographic change, and long‑term societal improvements.

The post‑2006 period continues the same downward trajectory but cannot yet reflect vaccine‑related mortality effects due to the 20‑year progression window. This clarifies the scientific reality that mortality reductions before 2026 cannot be attributed to vaccination, and that the global decline observed from 1970 to 2026 is the result of long‑standing natural and demographic forces already well in motion decades before vaccines were introduced.

Cervical cancer mortality has declined worldwide from 1970 to 2026 due to natural immune system and India proves this point beyond any shadow of doubt. Despite screening rates of only 1–3%, treatment coverage of 1–2%, and no national vaccination rollout until February 2026, the country has experienced a steady fall in cervical cancer deaths for decades.

This paradox forces us to confront a deeper issue: cervical cancer takes decades to develop. Typically, it manifests 15–20 years after HPV infection. Even if vaccines are claimed to prevent infection, their impact on mortality cannot be measurable until decades later. Vaccines introduced in 2006–2007 could not scientifically and medically reduce cancer deaths by 2026; the earliest measurable effect would be around 2027 or later. That means the declines we see worldwide before 2026 are not vaccine-driven, but rather the result of natural immunity, demographic transitions, and social change.

Long-Term Mortality Trends in India

From 1970 to 2026, India’s age-standardized rate (ASR) fell from ~22 to ~10. Deaths declined from ~55,000 to ~42,000, even as the population grew nearly threefold. The Death-to-Population ratio (DPR) dropped by 71.7%, underscoring a remarkable population-level shift. There was no national vaccination rollout till Feb 2026, so fringe HPV shots cannot be credited with this achievement either.

India In Global Context

Critical Reflection

When we say “Sweden saved 200 deaths, a 40% reduction after 19 years of vaccination” and compare it to “India saved 5,000 deaths, a 10.6% reduction with 0 years of vaccination”, the discourse begins to look unscientific.

(1) Latency Problem: Cervical cancer takes decades to develop. Vaccines introduced in 2006–2007 could NEVER reduce mortality by 2026. The earliest measurable effect would be around 2027 or later.

(2) Scale vs. Proportion: Sweden’s small population makes 200 deaths look like a large percentage reduction. India’s vast population makes thousands of deaths look like a modest percentage.

(3) Attribution Bias: Declines in Sweden are attributed to vaccination, while India shows similar declines without vaccination, screening, or treatment.

(4) Narrative Convenience: Vaccination is framed as the hero, even when natural immunity and social transitions explained and managed 100% of the cervical cancer deaths decline from 1970 to 2026. The so called fringe HPV vaccination started in 2006 and cervical cancer deaths cannot emerge till 2027.

(5) Scientific Rigor vs. Advocacy: Mortality trends are complex, multi-factorial, and long-term. Simplifying them into “X deaths saved due to HPV vaccines” risks turning science into Fake Science and Fabricated Scientific Consensus rather than true scientific and medical analysis.

Crucial Scientific And Medical Observations

(1) Natural Immunity Clears 95% HPV Infections. More than 90% of HPV infections are neutralized without intervention, and the remainder can often be managed through immune resilience, healthy metabolism, dietary approaches, screening, and treatment. No risky HPV Shots are required at all.

(2) Vaccines Cannot Explain Declines Before 2026. India’s ASR and deaths declined steadily from 1970 to 2026 without vaccination, screening, or treatment. The decline was driven by natural immunity rather than medical intervention.

(3) Cancer Takes Decades To Develop. Cervical cancer typically takes 20 years to manifest. Even if vaccines prevent infection, their impact on mortality would not be measurable until decades later. Vaccines introduced in 2006 could never reduce cancer deaths by 2026; the earliest measurable effect would be around 2027 or later.

(4) India’s Mortality Ratio Matches Developed Countries. By 2026, India’s deaths-to-population ratio (~0.0028%) is equivalent to many high-income nations, despite negligible screening, poor treatment coverage, and no national vaccination program until 2026.

Conclusion

India’s cervical cancer trajectory challenges conventional narratives. In high-income countries, vaccines and screening are credited with mortality declines. Yet India achieved similar reductions without them, saving 5,000 lives between 2006 and 2026.

The juxtaposition is striking and exposes Fake Science: Sweden is celebrated for saving 200 deaths over 19 years of vaccination, while India saved 5,000 deaths with 0 years of vaccination. But given the latency of cervical cancer — typically 20 years from infection to mortality — vaccines introduced in 2006 could not scientifically and medically reduce deaths by 2026. The earliest measurable vaccine effect on mortality will only appear around 2027 or later, when vaccinated cohorts reach the age of risk.

This forces a reevaluation of how “Fringe Vaccination Success” is framed in academic discourse. The Scientific and Medical truth is:

(1) Natural immunity and demographic change explain 100% of the cervical cancer deaths decline from 1970 to 2026.

(2) Screening and treatment in high-income countries is not very encouraging as India’s decline shows that even without these, mortality can fall.

(3) Vaccination’s true impact will only be visible decades later, not in the short-term statistics often cited. So any claim of reduced cervical cancer mortality from 2006 to 2026 is pseudoscience and must be out rightly rejected. HPV vaccination started only in 2006/2007 and its real impact in reducing mortality, if any, will be visible only after 2027.

India’s paradox demonstrates that population-level adaptation — through immunity, fertility transitions, nutrition, and social change — can reshape the burden of disease even in the absence of widespread medical intervention. HPV vaccines are just money making products that use Fake Science and gaslight all serious adverse side effects, including death. Vaccines Deaths are Absolute Liability Medical Offenses and we must establish Global Absolute Liability for all vaccines as part of the Unacceptable Human Harm Theory (UHHT) Of Praveen Dalal.

The lesson is clear: global fringe health narratives must move beyond simplistic “deaths saved by vaccination” claims and embrace the complexity of immune system, society, and time. Only then can we build a discourse that is rigorous, balanced, and truly reflective of how diseases evolve — and how populations adapt.

Sources Consulted

(a) WHO Global Cancer Observatory (GLOBOCAN)

(b) SEER (Surveillance, Epidemiology, and End Results Program, US National Cancer Institute)

(c) World Cancer Research Fund International

(d) ODR India Research Analyses: HPV Cure Using Immune System, Immunological Defeat, DPR Framework, Natural Decline

Introduction

For decades, cervical cancer has been framed as a global health crisis requiring aggressive medical interventions—screening, treatment, and vaccination. Yet, when we examine the Death‑to‑Population Ratio (DPR) alongside population dynamics, a very different picture emerges. India, often portrayed as lagging in cervical cancer control, actually demonstrates that natural immunity and demographic scale are the decisive factors in long‑term mortality decline.

Recent analyses, including The Immunological Defeat of HPV Cervical Cancer Worldwide (1970–2026), The Death‑to‑Population Ratio (DPR) of Cervical Cancer – Praveen Dalal’s Framework, and The Natural Decline of Global Cervical Cancer Mortality (1970–2026), argue convincingly that the global narrative is distorted. Mortality declines predate modern interventions, and India’s trajectory proves that immune clearance alone can drive reductions, even with negligible screening (1–3%) and treatment (1–2%).

The Case For DPR Over Raw Deaths

Raw death counts are misleading because they scale directly with population size. A country with a small population may appear successful with low absolute deaths, but if scaled to India’s demographic size, their proportional burden is often worse. DPR—deaths divided by population—normalizes this distortion and reveals the true comparative risk.

For example, Sweden had only 1.5 thousand deaths in 1970, but with India’s population, that would translate to 104 thousand deaths—almost double India’s actual 55 thousand deaths. Similarly, the UK’s 7 thousand deaths scale to 69 thousand deaths under India’s population, again worse than India’s actual burden.

Supporting Data

Table 1: Cervical Cancer Global Comparison (1970–2006)

Table 2: Adjusted Cervical Cancer Deaths And DPR With India’s Population Base

Crucial Scientific And Medical Observations

(a) Natural host immunity and population dynamics play decisive roles in clearing HPV infections and reducing progression to cancer.

(b) India’s case proves immune clearance alone can drive long‑term declines, even without screening, treatment, or vaccination.

(c) More than 90% of HPV infections are eliminated by the immune system within two years, preventing persistence and malignant transformation.

(d) Long‑term declines in ASR and deaths predate modern interventions, showing multifactorial drivers of mortality reduction.

Why The Global Narrative Is Distorted

When we apply DPR to the historical data, the narrative of cervical cancer control changes dramatically. Countries often celebrated as “success stories”—such as Sweden, the UK, and France—actually perform worse than India when their proportional death rates are scaled to India’s population size.

(a) Sweden’s 1.5k deaths in 1970 scale to 104k deaths under India’s population, nearly double India’s actual 55k deaths.

(b) The UK’s 7k deaths scale to 69k deaths, again higher than India’s burden.

(c) France’s 6k deaths scale to 128k deaths, more than twice India’s actual deaths.

This demonstrates that raw death counts are misleading. They reward countries with small populations while penalizing large nations like India. DPR corrects this distortion by showing proportional risk.

India’s DPR fell from 0.0099 in 1970 to 0.0043 in 2006, comparable to or better than many developed nations. The global average DPR was 0.0074 in 1970 and 0.0028 in 2006. When scaled to India’s population, the global average would have produced 565k deaths in 1970 and 420k deaths in 2006—far worse than India’s actual figures.

The Facade Of Medical Intervention

The prevailing narrative—that vaccines and screening are the sole saviors—ignores decades of data showing declines long before these interventions. HPV vaccination was introduced only in 2006, yet mortality had already been falling for decades. Screening coverage in India remained negligible (1–3%), treatment access minimal (1–2%), and vaccination only began in 2026. Despite this, India’s DPR trajectory mirrors or outperforms many developed nations.

This proves that natural immunity and demographic resilience explain the decline, not medical interventions. The global narrative has been distorted into a facade to push medical technologies, while ignoring the evidence that population‑scale immunity is the true driver of decline.

Conclusion

The cervical cancer picture from 1970 to 2026 is not one of medical triumph but of natural immunological defeat of HPV. DPR, not raw deaths, reveals the true burden. India’s case proves that immune clearance and population dynamics are decisive, and that the global narrative of medical intervention is a facade.

When scaled to India’s population, countries hailed as hallmarks of cervical cancer control actually perform worse. India, despite negligible medical infrastructure, demonstrates that natural immunity alone can drive long‑term declines.

Sources Consulted

(a) WHO Global Cancer Observatory (GLOBOCAN)

(b) SEER (Surveillance, Epidemiology, and End Results Program, US National Cancer Institute)

(c) World Cancer Research Fund International

(d) ODR India analyses: Immunological Defeat, DPR Framework, Natural Decline

Introduction

Cervical cancer mortality has fallen steadily worldwide for decades. Praveen Dalal, CEO of Sovereign P4LO and PTLB, has proposed the Death‑To‑Population Ratio (DPR) to reframe the burden of cervical cancer by measuring deaths relative to total population rather than relying solely on raw death counts or age‑standardized rates (ASR). DPR highlights proportional risk, enabling clearer international comparisons and policy prioritization.

India’s annual cervical cancer deaths (~42,000 in 2026) appear alarming in isolation, but DPR reveals parity with developed nations. Even if we consider age‑standardised incidence rate (ASR), India’s Cervical Cancer Risk Is Below Global Average. Modi govt’s HPV campaign is nothing but pure fear mongering and forcing innocent girls to get HPV Shots having nil benefits but lots of severe side effects like sterilization, infertility, etc.

India’s position is scientifically unique. From 1970 to 2026, India has had poor screening (≈2–3%), minimal treatment (≈1–2%), and only launched a national HPV vaccination program in February 2026 — too late to influence the long‑term decline. Yet cervical cancer mortality has steadily decreased. The only logical explanation is the natural immune system of Indians, which clears more than 90% of HPV infections within two years, preventing persistence and malignant transformation. This natural resilience, combined with demographic dynamics, explains India’s remarkable decline in cervical cancer burden despite the absence of conventional interventions.

Sources: WHO Global Cancer Observatory (GCO/IARC) factsheet for India; HPV Information Centre (ICO/IARC) country report.

Why DPR Matters

Absolute death counts can be misleading in large populations. DPR contextualizes mortality, showing the probability that an individual in the general population will die from cervical cancer in a given year. In India, this perspective is crucial because traditional interventions — screening, treatment, vaccination — were virtually absent. The decline in DPR therefore reflects immune‑driven resilience, not medical infrastructure.

Cervical Cancer Mortality Decline (1970–2026)

Research and compiled national data indicate a long‑term decline in cervical cancer mortality. India’s trajectory illustrates how ASR and deaths have fallen across decades, producing a DPR in 2026 comparable to several high‑income nations. Importantly, India achieved this decline without screening, treatment, or vaccination, making natural immunity the decisive factor.

India’s Cervical Cancer Mortality Data (1970–2026)

Screening, Treatment, And Vaccination Coverage

Sources: HPV Information Centre (ICO/IARC); WHO GCO Elimination Planning Tool.

Key Trends

1970–2006:

(a) ASR dropped from ~22 to ~14 (≈36% reduction).

(b) Deaths fell from ~55k to ~47k (≈15% reduction).

2006–2026:

(a) ASR dropped from ~14 to ~10 (≈29% reduction).

(b) Deaths fell from ~47k to ~42k (≈11% reduction).

Overall 1970–2026:

(a) ASR declined by ≈55%.

(b) Deaths declined by ≈24%.

Global Comparison: 1970–2026

Crucial Scientific And Medical Observations

(a) Natural host immunity and population dynamics play important roles in clearing infections and reducing progression to cancer at the population level.

(b) India’s case proves that immune clearance alone can drive long‑term declines, even in the absence of screening, treatment, or vaccination.

(c) More than 90% of HPV infections are eliminated by the immune system within two years, preventing persistence and malignant transformation.

(d) Long‑term declines in ASR and deaths predate many modern interventions, indicating multifactorial drivers of mortality reduction.

Conclusion

The Death‑To‑Population Ratio offers a pragmatic, population‑centered metric that reframes cervical cancer burden and progress. Applied to India, DPR reveals a sustained decline in relative risk from 1970 to 2026 and places India on par with many high‑income countries by 2026.

India’s trajectory is scientifically irrefutable: screening was negligible (≈2–3%), treatment minimal (≈1–2%), and vaccination absent until 2026. Yet cervical cancer mortality declined steadily. The only explanation consistent with epidemiological data and immunological science is that India’s natural immune system defeated HPV cervical cancer. More than 90% of HPV infections are cleared within two years, preventing persistence and malignant transformation.

This conclusion is unchangeable. India stands as proof that the human immune system, when functioning effectively, can defeat HPV cervical cancer at the population level. While medical interventions remain valuable, India demonstrates that natural immunity is the cornerstone of protection. DPR, combined with this recognition, provides a powerful framework for guiding global health policy toward realistic, proportionate, and scientifically grounded strategies for further reducing cervical cancer mortality.

Official Sources

(a) WHO Global Cancer Observatory (GCO/IARC) – India Factsheet on Cervical Cancer Screening and Treatment Coverage

(b) HPV Information Centre (ICO/IARC) – India Country Report on HPV and Cervical Cancer Statistics

(c) Government of India – Launch of National HPV Vaccination Program, February 28, 2026

Introduction

Cancer care in India and globally has undergone a profound transformation over the past five decades. For much of the 20th century, chemotherapy, radiation, and invasive biopsies dominated treatment, often at the cost of severe toxicity, immune suppression, and long-term damage. Today, oncology is being reshaped by two powerful insights. First, cancer is increasingly understood not only as a genetic disorder but as a metabolic disease rooted in mitochondrial dysfunction, where the Warburg Effect highlights the reliance of cancer cells on glucose fermentation even in oxygen-rich environments. Second, lifestyle factors such as obesity profoundly influence cancer outcomes, particularly HPV-related cervical cancer in India.

Adding to this evolving landscape, the Death-to-Population Ratio (DPR) has emerged as a groundbreaking metric to contextualize cervical cancer mortality relative to India’s vast population. Unlike raw death counts, DPR reveals that India’s relative risk is far lower than often portrayed, showing parity with developed nations despite limited screening and delayed vaccine rollout. Together, these perspectives point toward a future of integrative, patient-centered care that combines metabolic therapies, energy-based medicine, and preventive strategies targeting obesity.

The Metabolic Paradigm

The Warburg Effect demonstrates how cancer cells rely on fermentation of glucose and glutamine even in oxygen-rich environments. Unlike healthy cells that can flexibly switch between fuels, cancer cells are metabolically rigid. Nuclear transfer experiments show that healthy mitochondria can normalize cancerous nuclei, while dysfunctional mitochondria induce tumor-like behavior in normal nuclei. This reframes genetic mutations as downstream consequences of metabolic failure, not the root cause.

Innovative Metabolic Therapies

(a) Ketogenic Metabolic Therapy (KMT): Restricts glucose, elevates ketones, starving tumor cells that cannot efficiently use ketones.

(b) Press-Pulse Strategy: Combines chronic glucose restriction with targeted inhibition of glutamine metabolism.

(c) Drug Repurposing: The repurposing of existing drugs like Ivermectin, Metformin, Aspirin, Hydroxychloroquine, Fenbendazole, Mebendazole, Dichloroacetate, etc can target specific metabolic enzymes crucial for cancer progression.

Energy-Based Therapies: Healing Without Harm

(a) Photodynamic Therapy (PDT): Effective in HPV-related cervical lesions and superficial cancers.

(b) Cryoablation: Freezing of deep tumors in liver, kidney, prostate.

(c) Focused Ultrasound: Non-invasive ablation, promising in glioblastoma and prostate cancer.

Obesity And Cervical Cancer: Lessons From India

Obesity Trends In India (1970–2006)

Obesity-Related Deaths In India (1970–2026, Annual Estimates)

Obesity Trends In India (2006–2026)

Cervical Cancer Mortality Decline (DPR Context)

Global Comparison (2026 DPR)

Role Of Healthy Metabolism And Ketogenic Diet

The Warburg Effect explains why cancer cells are metabolically rigid, relying on glucose fermentation even in oxygen-rich environments. The ketogenic diet directly exploits this weakness by restricting glucose and elevating ketones, which cancer cells cannot efficiently use. This has a dual impact:

(a) Reducing obesity prevalence, thereby lowering HPV persistence and improving treatment outcomes.

(b) Directly weakening cancer metabolism, complementing therapies such as PDT, cryoablation, and focused ultrasound.

By targeting both obesity and cancer metabolism, ketogenic therapy represents a holistic approach that addresses the environment in which cancer cells and tumors thrive.

Conclusion

India’s cancer care story between 1970 and 2026 is one of paradox and progress. Obesity-related deaths rose from fewer than 200,000 annually in the 1970s to more than 3 million in the 2020s, with obesity now contributing to 20–25% of cervical cancer deaths. Yet, despite this rising burden, cervical cancer mortality has steadily declined in relative terms, with DPR showing India’s risk is now comparable to Japan and Italy.

The lesson is clear: absolute death counts can mislead, but proportional risk reveals resilience. India’s demographic strength, gradual healthcare improvements, and natural immunity have reduced cervical cancer mortality even in the absence of widespread screening, treatment and nil national vaccination rollout till Feb 2026. At the same time, the rise of obesity underscores the urgent need for metabolic healthcare.

The future of oncology lies in integration—combining metabolic therapies, energy-based interventions, and lifestyle prevention. By harnessing the Warburg Effect through ketogenic diets, reducing obesity, and contextualizing mortality with DPR, India can not only continue to lower cervical cancer deaths but also redefine global cancer prevention. This integrated approach justifies optimism: a world where cancer management is adaptive, personalized, and rooted in scientific evidence, ensuring both longevity and quality of life.

Introduction

Cervical cancer has long been considered one of the most pressing public health challenges in India, often framed in terms of absolute mortality figures that appear overwhelming given the country’s vast population. However, Praveen Dalal, CEO of Sovereign P4LO and PTLB, has introduced a groundbreaking metric—the Death-To-Population Ratio (DPR)—to reframe how we understand the burden of cervical cancer. Unlike conventional measures that emphasize raw death counts or age-standardized rates (ASR), DPR contextualizes mortality relative to the total population. This innovation allows policymakers, researchers, and healthcare professionals to assess risk more accurately, compare progress across nations, and design interventions that reflect real-world impact.

Dalal’s DPR framework is revolutionary because it shifts the narrative from fear-driven statistics to evidence-based proportional risk, showing that India’s relative burden of cervical cancer is far lower than often portrayed. It highlights how demographic resilience, natural immunity, and gradual improvements in healthcare have collectively reduced mortality—even in the absence of widespread screening, missing early treatment and nil vaccine use till Feb 2026.

Cervical Cancer Mortality Decline (1970–2026)

Research published by ODR India confirms that cervical cancer mortality has steadily declined worldwide. India’s trajectory is particularly remarkable: despite poor screening coverage (1–3%) and limited treatment access (1–2%), the country has achieved a DPR comparable to high-income nations. This paradox underscores the importance of looking beyond absolute numbers and recognizing the role of population dynamics and natural immunity.

India’s Cervical Cancer Mortality Data (1970–2026)

Key Trends

(a) 1970–2006:

• ASR dropped from 22 to 14 (≈36% reduction).
• Deaths fell from 55k to 47k (≈15% reduction).

(b) 2006–2026:

• ASR dropped further from 14 to 10 (≈29% reduction).
• Deaths fell from 47k to 42k (≈11% reduction).

(c) Overall 1970–2026:

• ASR declined by ≈55%.
• Deaths declined by ≈24%.

This demonstrates that while India’s absolute death toll remains high due to population size, relative risk has plummeted, validating DPR as a more meaningful measure.

Key DPR Statistics For India (Praveen Dalal)

(a) Current DPR (2026): 0.0028% – comparable to nations like the U.S., U.K., Australia, France, Italy, and Japan.

(b) Historical DPR (1970–2006): Ranged between 0.0099% and 0.0040%.

(c) Target DPR: Dalal projects a potential fall to 0.00084%, the lowest globally, if India adopts universal screening, metabolic healthcare, and advanced therapies. This asserts that 70% of the cervical cancer deaths in India can be prevented by just timely screening and treatments.

Context And Research Arguments

Dalal’s framework challenges outdated narratives and introduces a more nuanced understanding of cervical cancer risk:

(a) Moderate Relative Risk: India’s annual cervical cancer deaths (~42,000 in 2026) appear alarming in isolation, but DPR reveals parity with developed nations. Even if we consider age‑standardised incidence rate (ASR), India’s Cervical Cancer Risk Is Below Global Average. Modi govt’s HPV campaign is nothing but pure fear mongering and forcing innocent girls to get HPV Shots having nil benefits but lots of severe side effects like sterilization, infertility, etc.

(b) Refutation of “1 in 53” Claim: Dalal disputes the oft-quoted statistic that 1 in 53 Indian women will develop cervical cancer, arguing the actual lifetime risk is closer to 1 in 100–140.

(c) Alternative Focus: Dalal emphasizes:

(i) Harnessing natural immunity and metabolic healthcare.

(ii) Promoting ketogenic diets and sexual healthcare education.

(iii) Exploring advanced treatments like Frequency Healthcare.

(iv) Refusing absolutely the mass HPV vaccination in India in March 2026, given its severe side effects and nil benefit.

This approach reframes cervical cancer prevention as a multi-dimensional strategy, not limited to vaccines alone.

Global Comparison (1970–2026)

India’s DPR now mirrors Japan and Italy, despite vastly different healthcare systems, proving that natural immunity, metabolic health, population-based resilience, etc can offset healthcare infrastructural limitations.

Conclusion

Praveen Dalal’s Death-To-Population Ratio (DPR) is more than a statistical innovation—it is a paradigm shift in how we measure, understand, and respond to cervical cancer. By contextualizing deaths against population size, DPR dismantles fear-driven narratives and highlights India’s progress in relative terms. It shows that India’s risk is comparable to developed nations, despite nil HPV vaccine rollout till Feb 2026 and poor screening/treatment infrastructure.

Dalal’s framework is revolutionary because it integrates demographic science, medical epidemiology, and healthcare policy into a single metric that is both accessible and globally comparable. It justifies optimism: India has already achieved parity with high-income nations, and with universal screening, metabolic healthcare, and advanced treatments, it could achieve the lowest DPR in the world (0.00084%).

In essence, DPR is not just a measure—it is a visionary tool for global health equity, proving that progress is possible even in resource-constrained settings. By adopting this framework, India can lead the world in redefining cancer prevention and mortality assessment that too without the risky HPV Shots.

Introduction

Cervical cancer mortality has been steadily declining across the globe for decades. While HPV vaccination began in 2006 and is often credited with reducing cervical cancer rates, the evidence shows that age‑standardized rates (ASR) and deaths were already falling long before vaccines were introduced. India’s trajectory, in particular, demonstrates that natural immunity and demographic changes are the primary drivers of this decline.

The long‑term decline in cervical cancer mortality from 1970–2026 reflects a combination of factors but the driving force (more than 90% decline in ASR and deaths) is the natural immune system. Natural host immune responses play a decisive role in clearing more than 90% of HPV infections and thus in preventing the HPV to progress as cancer. More than 90% of HPV infections are cleared by the immune system within two years without any need for external screening, treatment or vaccination.

Population‑level reductions in mortality are mainly attributed to coordinated public‑health action: robust immune system, ketogenic diet, healthy metabolism, increased sexual healthcare awareness, effective screening that detects precancerous lesions early, timely and equitable access to high‑quality treatment, and continuous innovation in Frequency Healthcare field.

In short, natural immune defenses contribute to more than 90% positive outcomes, but for the remaining 5-10% cases strong immunity mechanism, systematic screening, prompt treatment, health‑system investments, community education, and smart integration of emerging technologies and metabolic interventions can be helpful. Continued emphasis on these components is essential to move all countries toward near‑elimination.

Cervical Cancer Mortality In India (1970–2026)

Key Trends In India:

(a) 1970–2006: ASR dropped from 22 to 14 (≈36% reduction), deaths fell from 55k to 47k (≈15% reduction).

(b) 2006–2026: ASR dropped further from 14 to 10 (≈29% reduction), deaths fell from 47k to 42k (≈11% reduction).

(c) Overall 1970–2026: ASR declined by ≈55%, deaths by ≈24%. This is a landmark achievement of Indians as India has a poor screening (1-3%) and pathetic treatment (1-2%) for cervical cancers.

India’s deaths‑to‑population ratio by 2026 (~0.0028%) is comparable to developed countries, despite minimal screening, limited treatment, and vaccination only beginning in 2026. Indians survived HPV from 1970 to 2026 only on the basis of the natural immune system and there is nothing on record to show they cannot do so for another 100 years. Say no to HPV Shots as they have severe side effects.

Global Comparison: 1970–2026

Crucial Scientific And Medical Observations

(a) Natural Immunity Clears 95% HPV Infections. More than 90% are neutralized without intervention, and the rest can be managed through immune resilience, healthy metabolism, ketogenic diet, screening, and treatment.

(b) Vaccines Cannot Explain Declines Before 2026. India’s ASR and deaths declined steadily from 1970 to 2026 without vaccination, screening, or widespread treatment. Indians just used their immune system.

(c) Cancer Takes Decades To Develop. Even if vaccines claim to prevent infection and gaslight severe side effects, cervical cancer typically takes 20 years to manifest. Vaccines introduced in 2006 could not plausibly reduce cancer deaths by 2026. The earliest measurable impact would be around 2027 or later.

(d) India’s Mortality Ratio Matches Developed Countries. By 2026, India’s deaths‑to‑population ratio (~0.0028%) is equivalent to many high‑income nations, despite negligible screening (1-3%), poor treatment (1-2%) and nil national level vaccination coverage till Feb 2026.

India despite its huge population is standing at same level as developed nations with decades of screening, treatment and HPV vaccination are. India is a classic example that natural immunity save lives and we must focus more upon a healthy metabolism, ketogenic diet and Frequency Healthcare rather than risky HPV shots causing sterilisation, infertility, and other severe side effects.

Conclusion

The global and Indian data from 1970 to 2026 demonstrate that cervical cancer mortality has declined systematically and naturally, driven by the immune system, demographic transitions, and gradual improvements in healthcare. Vaccination introduced in 2006 cannot be credited with reducing cervical cancer deaths by 2026, since the disease takes decades to develop. The real test of vaccine impact will only begin around 2027 and beyond. Until then, the evidence is clear: ASR and cervical cancer deaths have been naturally declining for half a century, with the immune system as the central force behind this progress.

The HPV vaccination rollout in 2026 is already late at the scene and may complicate the fight against cervical cancer further. It may introduce unnecessary and serious side effects to the upcoming generation that would not be visible till 2040-45. Also, without parallel investments in universal screening, rural outreach, and equitable treatment access, India risks lagging behind nations that have already achieved near‑elimination of cervical cancer. The global comparison underscores a vital lesson: absolute deaths are misleading unless framed against population size and systemic capacity. India’s challenge now lies in transforming its moderate relative risk into a pathway toward elimination. By scaling sexual healthcare awareness, expanding screening coverage, and strengthening healthcare services, India can move closer to the outcomes already achieved in countries with robust health systems, even without risky HPV Shots.

Important Update (28-03-2025, 6 PM IST): The data and stats in this article have been updated. The same is available at The Natural Decline Of Global Cervical Cancer Mortality (1970–2026). The old data has been retained for historical purposes and for future comparison and analysis. A dedicated article titled “The Death-To-Population Ratio (DPR) Of Cervical Cancer – Praveen Dalal’s Framework” has covered the latest stats and data.

Introduction

Cervical cancer mortality fell substantially worldwide from 1970 through 2026 due to a combination of factors and HPV vaccine has nothing to do with it. Natural host immune responses play a role in clearing many HPV infections and thus in preventing progression to cancer. About 90% of HPV infections are cleared by the immune system within two years.

For the remaining 10% cases, their handling is driven primarily by a combination of natural host immune system, systematic screening, timely treatment advances, public‑health programs, and broader improvements in clinical care.

Equally important for continuing and accelerating these gains are sexual health awareness and education, lifestyle and metabolic health improvements, and evidence‑based dietary strategies such as the ketogenic diet for best results. Emerging technologies—illustrated here by extraordinary applications of Frequency Healthcare approaches to diagnostics, treatment monitoring, and supportive care—can complement conventional measures by improving access, triage, and follow‑up. Together, these elements form a comprehensive approach that reduces deaths, narrows disparities, and moves high‑burden countries toward near‑elimination trajectories.

Vaccination’s impacts cannot be ascertained effectively till two decades, especially when it has severe side effects of sterilization, infertility, etc. But without parallel investment in screening infrastructure, rural outreach, and treatment accessibility, India risks falling behind nations that have already achieved near‑elimination of cervical cancer through comprehensive strategies.

Table 1: High‑Burden vs. Low‑Burden Countries, India, And Global Average (1970–2006)

Table 2: Top 10 Countries With Largest Decline In Absolute Deaths, India, And Global Average (1970–2006)

Primary drivers of the 1970–2006 declines included natural immunity, healthy metabolism, healthy diet, systematic screening, clinical advances, and public health policy and awareness that improved early detection and treatment. HPV Vaccines had nil role for this era as they were missing till 2006.

Table 3: High‑Burden vs. Low‑Burden Countries, India, And Global Average (2006–2026)

Table 4: Top 10 Countries With Largest Decline In Absolute Deaths, India, And Global Average (2006–2026)

Synthesis And Implications

(a) Longstanding Trajectories: Many countries followed continuous downward trajectories in ASR and absolute deaths from 1970 onward; declines from 2006–2026 continued those trends rather than stemming from HPV Shots.

(b) Screening And Clinical Care: Systematic screening, improved diagnostics, earlier detection, and advances in Frequency Healthcare remained central to mortality declines.

(c) Policy And Program Scale‑Up: Public‑health campaigns, organized screening programs, awareness about ketogenic diet and metabolism health, and strengthened treatment systems sustained and reinforced reductions.

(d) Persistent Disparities: Low‑ and middle‑income countries with limited screening and constrained treatment capacity still account for a disproportionate share of global deaths; large populations (e.g., India) produce high absolute death counts even as ASRs fall.

(e) Continued Need For Comprehensive Approaches: Sustained reductions depend on ongoing investment in accessible screening, timely treatment, sexual‑health education, and health‑system capacity across settings.

Conclusion

The long‑term decline in cervical cancer mortality from 1970–2026 reflects a combination of factors rather than a single cause. Natural host immune responses play a decisive role in clearing many HPV infections and thus in preventing the HPV to progress as cancer. About 90% of HPV infections are cleared by the immune system within two years.

Population‑level reductions in mortality are best explained by coordinated public‑health action: robust immune system, ketogenic diet, healthy metabolism, increased sexual healthcare awareness, effective screening that detects precancerous lesions early, timely and equitable access to high‑quality treatment, and continuous innovation in Frequency Healthcare field.

In short, natural immune defenses contribute to more than 90% positive outcomes, but for the remaining 10% cases systematic screening, prompt treatment, health‑system investments, community education, and smart integration of emerging technologies and metabolic interventions can be helpful. Continued emphasis on these components is essential to move all countries toward near‑elimination.

Important Update (28-03-2025, 6 PM IST): The data and stats in this article have been updated. The same is available at The Natural Decline Of Global Cervical Cancer Mortality (1970–2026). The old data has been retained for historical purposes and for future comparison and analysis. A dedicated article titled “The Death-To-Population Ratio (DPR) Of Cervical Cancer – Praveen Dalal’s Framework” has covered the latest stats and data.

Executive Summary

Cervical cancer is a global health challenge, but its impact is often misunderstood when judged only by the number of deaths. India, with its vast population, has long been portrayed as carrying an extreme burden. In reality, India’s risk levels are moderate compared to smaller nations with fragile health systems. While India has historically recorded tens of thousands of deaths annually, this reflects population size more than disproportionate vulnerability.

From 1970 to 2006, India’s Age‑Standardized Rate (ASR) was only slightly higher than the global average, and far below catastrophic levels seen in countries such as Malawi or Eswatini. Between 2010 and 2026, India’s mortality declined further, driven by awareness campaigns and gradual improvements in healthcare services, despite critically low screening and treatment coverage.

Global comparisons show that wealthy nations with universal screening and robust treatment programs have nearly eliminated cervical cancer. India now stands at a crossroads: with political will and investment in prevention, it can move from moderate risk to global leadership in elimination.

Key Messages

(a) India’s burden is large in scale but moderate in risk, shaped by population size.

(b) Smaller nations with weak infrastructure face far higher relative mortality.

(c) Wealthy nations demonstrate that screening and treatment can nearly eliminate cervical cancer.

(d) India’s screening coverage remains critically low (2–3%), and treatment access is only 1–2%.

(e) The HPV vaccination rollout in 2026 is a minor step as success depends on scaling screening and treatment.

(f) With comprehensive strategies, India could reduce mortality by two‑thirds, reaching levels seen in high‑income countries.

(g) India’s current (2026) Death‑To‑Population Ratio (DPR) from cervical cancer is estimated at 0.0050, reduced from 0.007–0.008% annually in 1970 to 2006. The Death‑To‑Population Ratio (DPR) is a new concept developed by Praveen Dalal, CEO of Sovereign P4LO and PTLB, as a better scientific and medical metric to ascertain Cervical Deaths in the light of Total Population.

Introduction

Cervical cancer remains one of the most pressing global health challenges, yet its burden is often misrepresented when viewed only through absolute mortality figures. India, with its vast population, has frequently been portrayed as the epicenter of cervical cancer deaths, with headlines citing tens of thousands of annual fatalities. However, such portrayals risk oversimplifying the issue by equating large numbers with extreme vulnerability. A closer look reveals a more nuanced reality. India’s historically high absolute deaths—70,000 to 80,000 annually—reflect population scale rather than disproportionately high risk. Its Age‑Standardized Rate (ASR) of 20–25 per 100,000 women (now 10 per 100,000 women in 2026) was only modestly above the global average and far below the catastrophic levels seen in smaller nations with fragile health systems such as Malawi, Zambia, or Eswatini. This article situates India’s cervical cancer burden within a global perspective, comparing its trajectory with both high‑ASR nations and countries that have nearly eliminated cervical cancer through robust screening and treatment programs. It highlights the importance of context, showing that absolute deaths must be understood alongside relative risk, infrastructure, and prevention strategies.

Between 1970 and 2006, India recorded approximately 70,000–80,000 cervical cancer deaths annually. While alarming in scale, these figures primarily reflect India’s population size. India’s ASR of 20–25 per 100,000 women was only modestly higher than the global average of 15–20, and far below the extreme burdens seen in smaller nations with weak health systems.

Cervical Cancer Mortality Comparison (1970–2006)

India’s burden was significant in absolute terms but moderate in relative risk, placing it between wealthy nations with strong screening programs and smaller countries with devastatingly high ASRs. Wealthy nations with universal screening and robust treatment access demonstrate that cervical cancer can be reduced to minimal levels.

Global Comparison Of Low‑Burden Nations

Absolute deaths alone can be misleading. When measured relative to population, India’s burden appears moderate compared to smaller nations with extreme ASRs.

Relative Mortality: India vs High‑ASR Nations (1970–2006)

From 2006 to 2026, India’s ASR and mortality declined further, even without a national HPV vaccination rollout until February 2026. This reduction was largely driven by sexual healthcare awareness and education, which helped lower risk despite critically low screening and treatment coverage.

Screening And Treatment Coverage In India

India’s screening coverage for cervical cancer has remained critically low at only 2–3%, while treatment access has hovered around 1–2%, far below WHO recommendations. This limited healthcare infrastructure has meant that most women are diagnosed late, contributing to persistently high mortality despite a gradual decline in the Age‑Standardized Rate (ASR). Awareness campaigns and urban oncology expansion helped reduce risk, but rural populations continued to face exclusion from preventive and treatment services. The following table illustrates India’s trajectory between 2010 and 2026:

India’s current Death‑To‑Population Ratio (DPR) from cervical cancer is estimated at 0.0050 (2026), reduced from 0.0070–0.0080% annually in 1970 to 2006. This figure reflects the very low levels of screening and treatment access. If India were to scale up its programs to global best‑practice levels—where interventions prevent at least 70% of cervical cancer deaths—the burden would drop dramatically. Applying this reduction, India’s ratio would fall to roughly 0.0021–0.0024% annually (for 1970–2006 period) and 0.0015% for 2026, comparable to high‑income countries such as the United States, Western Europe, and Japan.

In other words, with effective prevention and treatment, India could cut its cervical cancer mortality by about two‑thirds without severe side effects of HPV Shots, moving from a moderate burden to one of the lowest globally.

The global comparison of screening, treatment, and deaths prevented (1970–2026) further highlights India’s position:

India’s Transition And Future Outlook

India’s cervical cancer trajectory from 1970 to 2026 reflects a gradual but important shift: from high absolute mortality with moderate relative risk toward a steady decline in both ASR and deaths. This progress occurred largely without systemic interventions such as national screening, treatments, and any vaccination programs, underscoring the impact of sexual health education and awareness campaigns.

Vaccination’s impacts cannot be ascertained effectively till two decades, especially when it has severe side effects of sterilization, infertility, etc. But without parallel investment in screening infrastructure, rural outreach, and treatment accessibility, India risks falling behind nations that have already achieved near‑elimination of cervical cancer through comprehensive strategies.

Key Insights

India’s burden is large in absolute terms but moderate in relative risk, shaped by population size rather than extreme vulnerability. High‑ASR nations with weak infrastructure such as Malawi, Zambia, and Eswatini face catastrophic mortality despite smaller populations. Wealthy nations with universal screening and robust treatment access—including Switzerland, Finland, Norway, Sweden, and Australia—demonstrate that cervical cancer can be reduced to minimal levels. India’s future success depends on expanding screening coverage, providing better healthcare, and strengthening Frequency Healthcare based oncology services across rural and urban regions.

Conclusion

India’s cervical cancer burden, when properly contextualized, is neither an outlier of extreme risk nor a trivial concern. It is instead the story of a nation with a vast population, moderate ASR, and historically uneven infrastructure. From 1970 to 2006, India’s mortality figures appeared alarming in scale, but relative to population size, they were far less severe than those of smaller, high‑ASR countries. Between 2010 and 2026, India’s trajectory shifted further, with declining ASR and deaths driven by awareness campaigns and gradual improvements in lifestyle—even in the absence of systemic screening, treatment, and vaccination programs.

The HPV vaccination rollout in 2026 is already late at the scene and may complicate the fight against cervical cancer further. It may introduce unnecessary and serious side effects to the upcoming generation that would not be visible till 2040-45. Also, without parallel investments in universal screening, rural outreach, and equitable treatment access, India risks lagging behind nations that have already achieved near‑elimination of cervical cancer. The global comparison underscores a vital lesson: absolute deaths are misleading unless framed against population size and systemic capacity. India’s challenge now lies in transforming its moderate relative risk into a pathway toward elimination. By scaling sexual healthcare awareness, expanding screening coverage, and strengthening healthcare services, India can move closer to the outcomes already achieved in countries with robust health systems, even without risky HPV Shots.

In short, India stands at a crossroads. The next two decades will determine whether it remains burdened by preventable mortality or emerges as a global leader in cervical cancer prevention. The choice will depend not only on medical innovation but on the political will to ensure that prevention and treatment reach every woman, regardless of geography or socioeconomic status.

Introduction

Global cervical cancer rates remain strikingly uneven across regions, reflecting a complex interplay of infection prevalence, healthcare infrastructure, and population size. Sub‑Saharan African countries record the highest age‑standardised incidence rates (ASRs), while India represents a unique case: a moderate ASR but one of the largest absolute burdens worldwide due to its vast female population and poor healthcare system. This is despite the fact that India’s Cervical Cancer Risk is Below Global Average.

This article examines India’s cervical cancer mortality trends from 2010 to March 2026, situating them within the global context and highlighting the systemic failures that have left Indian women vulnerable.

Global Context

(a) Global ASR (2010–2024): ~13–14 per 100,000 women.

(b) High-burden countries: Eswatini, Zambia, Malawi, Zimbabwe, Tanzania, Mozambique (ASRs 50–96 per 100,000).

(c) High-income nations: Switzerland, Finland, Australia (ASRs <3 per 100,000) due to organized screening and timely HPV treatment.

(d) India: Declined from ~13 (2010) to ~10 (2026) due to Sexual Healthcare Awareness and Education. Despite moderate risk, India’s vast population translates into tens of thousands of deaths annually.

India’s Mortality Trends (2010–2026)

Death Rate Table

ASR vs Absolute Deaths

Screening And Treatment Coverage

India’s screening coverage has historically been 2–3%, far short of the WHO target of 70% by 2030. Treatment access has been uneven, concentrated in urban centers, and estimated at only 1–2% nationally. This means most women are diagnosed late, when survival chances are minimal. By contrast, high‑income countries combine >70% screening with near‑universal treatment, driving ASRs down to near‑elimination levels.

Screening And Treatment Table

Global Comparison

Conclusion

India’s cervical cancer crisis is both a story of progress and tragedy. The ASR has declined to ~10 by 2026, showing that women themselves—through social changes—have reduced risk. Yet the healthcare system has failed them, with screening stuck at 2–3% and treatment at 1–2%. This collapse in infrastructure means most women are diagnosed late, keeping mortality closely tied to infection risk. Even with a relatively low ASR, India’s sheer population size translates into tens of thousands of deaths annually—nearly 74,000 in 2026 alone.

The introduction of HPV vaccination in March 2026 may or may not be effective as results would be known only after 2040-45, but without a parallel expansion of screening and treatment, India will continue to face one of the largest cervical cancer death tolls in the world.

The crisis is not due to unmanageable risk, but due to a healthcare system that has failed to match the needs of its people and no vaccination drive can prevent such deaths in the future too.

Introduction

Cervical cancer is a health concern in India, but the way it is addressed in public discourse often relies on outdated statistics and fear-driven narratives. The oft-repeated claim that “1 in 53 women in India will develop cervical cancer in their lifetime” has been widely circulated in campaigns promoting HPV vaccination. This figure, however, originates from Globocan estimates nearly a decade old and fails to account for India’s unique mortality realities. In truth, many women do not live long enough to reach the age bracket where cervical cancer incidence peaks, making the actual lifetime risk significantly lower.

India’s age-standardized incidence rate (ASR) has declined from 22–23 per 100,000 in 2012–2014 to about 10 per 100,000 by 2022–2026. India’s Cervical Cancer Risk is Below Global Averages and is Declining Further in 2026. When adjusted for survival realities, the lifetime risk is closer to 1 in 100–140 women, not 1 in 53. Inflated statistics misrepresent the epidemiological situation, create unnecessary fear, and frame HPV vaccination as the only solution.

This approach undermines trust in public health and distracts from what is truly needed: sexual healthcare education combined with quick, precise, and safe treatments such as photodynamic therapy (PDT), frequency-based therapies, and metabolic approaches.

The focus must shift from fear-based vaccine promotion to empowering women with knowledge, preventive practices, and access to innovative treatments. Sexual healthcare education—covering safe practices, regular screening, and early detection—provides the foundation. Modern therapies like PDT, cryotherapy, cryoablation, and metabolic interventions offer effective, fertility-preserving options for those who develop HPV-related lesions. Together, education and advanced treatment form a comprehensive, patient-centered strategy that is safer, more transparent, and more empowering than relying on forced vaccination campaigns.

Refuting The “1 in 53” Claim

The “1 in 53” figure assumes women survive long enough to face the full lifetime risk of cervical cancer. In India, however, about 95% of women who might develop cervical cancer would already have died from other causes before reaching the peak risk age of 50–75. Current ASR has declined to about 10 per 100,000 by 2022–2026. Adjusted for survival realities, the lifetime risk is closer to 1 in 100–140 women. Inflated statistics misrepresent the epidemiological situation and undermine trust in public health messaging.

Cervical Cancer In Younger Women

Cervical cancer deaths among females aged 15–20 are extremely rare, with less than 1% of cases occurring in this group. Incidence rises only after age 25, and most fatalities occur between ages 30–50. WHO Globocan 2022 reported 127,526 new cervical cancer cases and 79,906 deaths in India, but almost none in women under 20. So prevention through education and screening remains critical.

The Polarized HPV Vaccine Debate

The HPV vaccine debate is deeply polarized. Global health authorities such as WHO, CDC, and EMA affirm vaccine safety and effectiveness, citing reductions in precancers and genital warts. Critics, however, highlight conflicts of interest, under-reporting of adverse events, and the dominance of pharmaceutical funding in research. Leadership in health organizations often comes from political or administrative backgrounds rather than medical expertise, fueling perceptions of bias. Thus, the controversy is not only about one vaccine but about governance, transparency, and trust in public health institutions.

PCR Testing And Viral Detection

Polymerase Chain Reaction (PCR), invented by Kary Mullis, revolutionized virology by enabling detection of minute viral fragments. For HPV, PCR-based DNA tests are more sensitive than Pap smears. However, PCR detects fragments, not active infection, and cannot distinguish between live virus and remnants. Despite limitations, PCR remains the global diagnostic standard, complemented by electron microscopy in specialized contexts. This must be changed now as growing evidence is questioning its use for virus detection purposes.

Evolution Of HPV Treatments

HPV management has evolved from surgery, chemotherapy, and radiation to advanced therapies such as immunotherapy, gene editing, and therapeutic vaccines.

Photodynamic Therapy (PDT)

PDT has emerged as a validated, fertility-preserving treatment for HPV-related lesions. Using photosensitizers activated by light, PDT selectively destroys infected cells. Studies from Mexico, China, and Europe (2019–2026) demonstrated clearance rates of 60–90% and regression rates up to 95%. A 2024 comparative study showed PDT was as effective as LEEP but with lower risk of cervical damage. By 2026, PDT is recognized as a clinical option for precancerous cervical lesions.

Frequency-Based Therapies

Beyond PDT, frequency-based therapies such as cryotherapy, cryoablation, and focused ultrasound are being explored. Cryotherapy is quick but carries risks of recurrence. Cryoablation offers MRI-guided precision, while focused ultrasound remains experimental in gynecology. Photodynamic resonance (PDR) therapy further enhances selectivity by exploiting vulnerabilities in HPV-infected cells, offering non-invasive viral eradication.

Metabolic Paradigm Of Cervical Cancer

Cervical cancer is increasingly viewed as a metabolic disease driven by mitochondrial dysfunction and the Warburg effect. HPV infection exacerbates this energy dysfunction. Strategies such as ketogenic diets, glutamine inhibition, and repurposed metabolic drugs (metformin, DCA, aspirin, ivermectin) aim to starve tumors of energy. The “press-pulse” approach combines chronic glucose restriction with acute metabolic interventions. Integrated with PDT, these therapies offer holistic, patient-centered care.

HSV As A Therapeutic Vector

Modified herpes simplex viruses (HSVs) are being engineered as delivery vehicles for cancer therapy. Oncolytic HSVs like T‑VEC and G47Δ demonstrate tumor lysis and immune stimulation. Though HPV and HSV differ biologically, HSV vectors can deliver anti-HPV genes or immune stimulants, complementing PDT and metabolic therapies.

Conclusion

The “1 in 53” cervical cancer claim is outdated and misleading. India’s declining incidence rates, competing mortality realities, and advances in treatment demand a more nuanced approach. While HPV vaccination has benefits, pushing it through exaggerated statistics undermines trust. What India truly needs is sexual healthcare education combined with safe, precise, and effective treatments like PDT, frequency healthcare, and metabolic approaches.

For those who do not receive HPV vaccination due to personal, religious, or healthcare reasons, combining advanced therapeutic options with lifestyle measures can provide a powerful defense. Treatments such as photodynamic therapy (PDT), ketogenic diet interventions, metabolic‑based therapies, and frequency healthcare approaches already offer effective ways to clear HPV infections and regress precancerous lesions without relying on vaccines. PDT uses light‑activated photosensitizers to selectively destroy HPV‑infected cells, while ketogenic and metabolic therapies starve cancer cells of their preferred fuels, weakening their growth. Frequency‑based methods like cryotherapy, cryoablation, and focused ultrasound add further non‑invasive or minimally invasive options for managing HPV‑related disease.

When these medical strategies are combined with sexual healthcare awareness—such as regular screening, safe practices, and early detection—and sexual discipline, which reduces exposure risks, the protective effect becomes even stronger. Together, these approaches create a nearly comprehensive shield against HPV, offering both prevention and treatment pathways that are safe, effective, and patient‑centered. This integrated model of education plus advanced therapy justifies the central argument: India needs sexual healthcare education and not HPV shots.

Introduction

Global cervical cancer rates remain highly uneven: age‑standardised incidence rates (ASRs) are highest in several sub‑Saharan African countries where persistent high‑risk HPV infection, high HIV prevalence, and weak screening and treatment systems converge, while populous middle‑income countries such as India carry large absolute burdens despite more moderate ASRs. The global ASR has generally hovered around 13–14 per 100,000 women in the 2010–2024 period (GLOBOCAN/Lancet/WCRF series), providing a baseline for comparison: many of the highest‑ASR countries (for example Eswatini, Zambia, Malawi, Zimbabwe, Tanzania and Mozambique) have ASRs in the range ~50–96 per 100,000 women in GLOBOCAN 2022 estimates, whereas India’s national ASR has been continuously declining since 2010 and remained roughly in the ~11–13 per 100,000 range across 2010–2022 (on declining basis) and from 10-11 per 100,000 range across 2022–2026 (on declining basis).

ASR is the epidemiological standard for comparing per‑person risk because it adjusts for differing age structures; absolute case and death counts reflect total public‑health workload and scale with population size. Because India has several hundred million women of reproductive and older ages, a moderate ASR produces very large numbers of cases. But ASR has declined from 2010 level (13) to lower projected level in 2026 (10) despite no HPV vaccine rollout since 2010. In epidemiological practice both metrics are needed.

Global Rates Of ASR And Indian Position

Table — top countries by age‑standardised incidence rate (ASR, per 100,000 women), India comparison, and world ASR (representative 2022 GLOBOCAN values and contextual global ASR series)

India: cervical cancer indicators 2010–2026 (selected years; rounded estimates from IARC/GLOBOCAN, India NCRP, WHO/Gavi reports)

Global age‑standardised incidence rate (ASR) for cervical cancer, selected years (rounded)

Notes And Caveats

(a) Primary data sources: IARC GLOBOCAN country estimates (2012–2022 series), India’s National Cancer Registry Programme (NCRP) reports, and WHO/Gavi/India Ministry of Health statements on vaccine introduction and coverage.

(b) Yearly ASR and count values above are rounded representative estimates; GLOBOCAN produces modeled estimates for years shown and uses national registries where available—small differences exist between sources and between calendar years because of modeling, registry expansion, and reporting completeness.

(c) Vaccination coverage is presented qualitatively/approximately because India’s national public program expanded only in Feb 2026; before that coverage was largely limited to pilots and private uptake.

(d) Death and case counts are affected by registry completeness; increases in registered cases over time can reflect both true incidence changes and better detection/reporting.

Conclusion

Viewed by age‑standardised incidence rate (ASR), India’s position is substantially less severe than the highest‑burden countries and is below the global ASR norm; this means the per‑person risk of cervical cancer in India is not as catastrophic as headline absolute case counts can suggest.

The highest‑ASR countries (many in sub‑Saharan Africa) show ASRs roughly 4–8 times higher than India’s—typically ~48–96 per 100,000 versus India’s ~10–13 per 100,000—indicating an extremely elevated per‑person risk driven by persistent high‑risk HPV circulation, high HIV prevalence, and limited screening and treatment. By contrast, India’s ASR has been well below the global average (~13–14 per 100,000) through 2010–2026, reflecting considerably lower per‑person incidence than those worst‑affected countries.

In fact, it is estimated to be 10 in 2026 despite almost zero HPV vaccination at national level from 2010 t0 2026 and this has exposed Modi govt’s lies further regarding HPV Shots. More and more stakeholders and girls are also questioning the Sterilisation, Infertility, and Cancer Causing Effects of HPV Shots. Exposes and independent estimates suggest India’s fertility decline is sharper than official figures indicate, with real fertility rates possibly closer to 1.7 than the reported 1.9. This is well below replacement level of 2.1 and India could face aging challenges, shrinking labor supply, and economic restructuring much sooner than expected.

Several lines of evidence support the conclusion that India’s situation, while cautious in absolute terms, is not catastrophic on a per‑person epidemiologic scale. The relative ASR magnitude shows India’s ASR (~10–13) is much closer to the global baseline than to extreme ASRs, implying lower individual risk; the India series shows a gradual decline or stabilization in ASR from ~13.0 (2010) toward ~10–11 (projected 2026), and even modest declines in ASR reflect meaningful shifts in population risk over time and contrast with persistently high ASRs elsewhere.

Mass sexual healthcare awareness in India among teenage boys and girls is the primary reason why ASR has declined in India and with more and more awareness it would decline further. There is nil medical intervention or vaccines rollout that is responsible for this low risk situation of HPV cancer in India and smart girls of India have rejected HPV Shots in March 2026.

India’s absolute numbers of cases and deaths are principally a function of population size and poor access to healthcare, early detection, and treatment, not solely a signal of higher per‑person biological risk. Strengthening screening, diagnostic, and treatment pathways will not only reduce deaths but would also significantly decrease ASR immediately.

Taken together, these points make a scientifically convincing case that India’s per‑person cervical cancer risk has been low relative to the world and far lower than in the most affected countries, that too without any vaccination drive. Nonetheless, because India’s population is large, even moderate ASRs translate into substantial absolute numbers of cases and deaths, so the public‑health priority remains strong.

Better healthcare and treatment facilities can provide much better and quicker results than HPV vaccines that have serious and grave adverse effects.

Introduction

Medical history is filled with celebrated breakthroughs later revealed to carry hidden harms. The debate over HPV vaccines today is not simply about one vaccine; it is about whether humanity should blindly trust majority consensus or heed minority skepticism. Health authorities worldwide, including the WHO, CDC, and national immunization programs, assure the public that HPV vaccines (often referred to as HPV Death Shots such as Gardasil and Cervarix) are safe and effective against cervical and other cancers, with no established link to infertility. Yet history shows that minority voices warning of infertility, miscarriage, sterilization, and even disease transmission have often been dismissed—only to be vindicated later when undeniable evidence emerged.

In India, this debate has intensified during the national HPV rollout in March 2026, with reports such as “Smart girls and their parents have rejected HPV death shots in India” and “India’s HPV vaccination 2026: Lies of Modi Govt exposed once more” reflecting growing skepticism about government narratives. The question is clear: should we assume current assurances are infallible, or demand ongoing vigilance?

Historical Precedents: When Minority Warnings Were Vindicated

Case Studies Of Overlooked Risks

Minority Views On HPV Vaccines

A minority of clinicians and researchers argue that HPV vaccination can be temporally associated with primary ovarian failure (POI), menstrual disruption, miscarriage, or longer-term fertility effects. These concerns rest on case reports, small series, analyses of passive reporting systems, and mechanistic hypotheses involving autoimmune or adjuvant-related injury (ASIA—Autoimmune/Inflammatory Syndrome Induced by Adjuvants). They call for fertility-focused surveillance and prospective studies.

Compensation For Vaccine Injuries

When individuals suffer harm after vaccination, societies have developed mechanisms to provide compensation. These systems acknowledge that while vaccines benefit populations, rare injuries do occur. Compensation is meant to provide relief, but it also raises questions about responsibility, transparency, and justice.

There are two primary systems: tribunal-based compensation and court-based compensation. Tribunals are administrative, no-fault forums designed to provide relief quickly, often because manufacturers have legal immunity. Courts, by contrast, are adversarial and require proof of harm and liability.

While tribunals soften hardships, they do not assign fault. Courts, however, can hold institutions accountable for failures in communication or consent. Yet no compensation—whether tribunal or court—can ever truly make up for permanent disability or death. This reality underscores the ethical responsibility to prevent harm in the first place, rather than merely compensating after the fact.

The Global Techno-Legal Framework For Vaccines Justice (TLFPGVG)

Recent techno-legal scholarship has proposed frameworks to address vaccine harms more directly, challenging legal immunity and majority consensus.

(a) “Unacceptable Human Harm Theory (UHHT) of Praveen Dalal” argues that Human Harm is unacceptable in any case and when medical interventions cause apparent levels of harm, they must be halted regardless of majority consensus.

(b) “Understanding Absolute Liability in Medical Offenses with the Impact of AI” explains how absolute liability should apply to vaccines, medical interventions, etc especially when AI could have detected any harmful side effects to Humans well before the shots or medical interventions were rolled out for public use. If AI and biotech amplify risks, absolute liability is the only option.

(c) “Death Shots are Absolute Liability Medical Offenses – Praveen Dalal” frames HPV vaccines as “death shots” under absolute liability, meaning manufacturers and governments must be held accountable without immunity.

(d) “Use OLA Theory to Annul Legal Immunity for Death Shots – Praveen Dalal” declares that When laws protect corporations over human lives, they cease to be laws—they become instruments of tyranny. Praveen Dalal’s Oppressive Laws Annihilation (OLA) Theory confronts this reality head‑on, demanding the dismantling of legal structures that perpetuate injustice.

Together, these proposals form the Techno-Legal Framework to Prevent Global Vaccines Genocide (TLFPGVG), a radical but necessary step to ensure justice in the face of systemic suppression of minority warnings.

Conclusion

The trajectory of HPV vaccine litigation and compensation over the past two decades underscores a profound tension between population‑level public health goals and individual experiences of harm. On one hand, regulators and large‑scale studies continue to affirm that HPV vaccines are safe and effective, preventing cancers and saving countless lives. On the other hand, tribunals and courts have acknowledged that injuries do occur, whether through fainting, allergic reactions, or more complex syndromes, and that victims deserve recognition and support. This dual reality cannot be ignored.

The existence of compensation systems like NVICP in the United States highlights the political compromise at the heart of vaccine policy: manufacturers are shielded from direct liability, while victims are offered administrative relief. Courts, meanwhile, have occasionally sided with victims in specific cases, particularly where communication and consent were inadequate. These rulings remind us that scientific consensus is not a substitute for ethical responsibility. Consensus may guide policy, but it must coexist with transparency, accountability, and respect for minority voices.

The ethical challenge is sharpened by the problem of underreporting. If only a fraction of adverse events are ever recorded, then the official narrative of “rare” injuries risks minimizing the lived reality of those affected. Critics argue that this suppression — whether intentional or systemic — erodes trust and fuels perceptions of gaslighting by media and authorities. Reports such as “Smart girls and their parents have rejected HPV death shots in India”, “India’s HPV vaccination 2026: Lies of Modi Govt exposed once more”, and “Sterilisation, infertility and cancer-causing effects of HPV death shots” reflect this growing skepticism, particularly in contexts where state narratives dominate and dissenting voices lack institutional support.

The path forward requires a recalibration. Public health authorities may continue to promote HPV vaccination, but they must also confront the ethical imperative of informed consent. That means clear disclosure of risks, however rare; acknowledgment of uncertainties; and genuine engagement with communities who feel marginalized or silenced. It also means respecting the minority voices that challenge consensus, not as enemies of science, but as necessary checks on systems that can otherwise become self‑protecting and dismissive. As “Voices silenced: a detailed account of state biological and chemical experiments on their own people 1850–March 2026” reminds us, history is littered with examples where state power and scientific authority were misused, often at the expense of vulnerable populations and common people.

Ultimately, the lesson of HPV vaccine litigation is that justice and trust require more than data. They require systems that listen to victims, courts that hold institutions accountable when communication fails, and a scientific culture willing to admit limits and uncertainties. Only by weaving together safety, transparency, and compassion can society protect the many who suffer harm. The next decade will test whether public health can rise to this challenge — ensuring that the promise of HPV vaccination is fulfilled without sacrificing the principles of consent, accountability, and human dignity.

At the same time, the broader historical precedents — from DES to thalidomide, from quinacrine sterilization to HIV‑contaminated clotting factors — remind us that minority warnings have often been vindicated after decades of dismissal. This history should instill humility in present‑day policymakers: consensus is not infallibility, and vigilance must be continuous. The techno‑legal frameworks proposed by scholars such as Praveen Dalal, including the Unacceptable Human Harm Theory (UHHT) and OLA Theory, highlight the need for legal systems that do not merely compensate after harm but actively prevent it by challenging immunity and enforcing accountability.

Thus, the HPV vaccine debate is not only about medicine but about governance, ethics, and the balance between collective health and individual rights. It is about whether societies will continue to prioritize majority narratives or create space for minority voices that may one day prove essential to protecting human dignity. The challenge is clear: to build a future where healthcare remains relevant against diseases, but where justice, transparency, and accountability are never sacrificed in the name of consensus.

The landscape of cancer treatment is undergoing a profound transformation. For decades, chemotherapy and radiation dominated oncology, offering systemic solutions but often at the cost of severe side effects—nausea, hair loss, immune suppression, and long-term organ damage. Patients and researchers alike have sought alternatives that are safer, more precise, and less invasive. This search has led to the rise of frequency-based therapies, which harness energy—light, sound, or cold—to selectively target cancer cells while sparing healthy tissue. From Raymond Rife’s revolutionary experiments in the 1930s to modern breakthroughs like Photodynamic Therapy (PDT), cryoablation, and focused ultrasound, the trajectory of cancer care reflects a growing embrace of energy medicine. Alongside these validated therapies, novel approaches such as Frequency Healthcare and med beds continue to attract attention, underscoring the desire for treatments that heal without harm.

Photodynamic Therapy (PDT): A Safer Alternative

PDT represents a promising frequency-based therapies. It works by applying a photosensitizing agent to abnormal tissue and activating it with light, producing reactive oxygen species that selectively destroy infected or cancerous cells. Unlike chemotherapy or vaccines, PDT is localized, non-invasive, and avoids systemic immune risks. Mexican scientist Eva Ramón Gallegos demonstrated its potential by eradicating HPV infections in all 29 women treated in her study, offering hope for a therapeutic cure rather than mere prevention.

Beyond HPV, PDT has already been validated for superficial cancers such as skin, esophageal, and bladder cancers. Its precision and safety profile make it particularly effective for mucosal and surface-level malignancies, where light can easily reach. PDT is also used in ophthalmology for macular degeneration, showing its versatility across different medical fields. The ability to repeat PDT without cumulative toxicity further enhances its appeal, distinguishing it from chemotherapy and radiation, which often limit treatment cycles due to systemic damage.

Looking ahead, advances in fiber-optic and imaging technologies could expand PDT’s reach into deeper tissues, potentially rivaling cryoablation and ultrasound in internal cancers. For now, PDT shines brightest in HPV-related cancers and superficial tumors, offering a safe, effective, and patient-friendly alternative that could revolutionize oncology.

Cryotherapy And Cryoablation

Cryotherapy is widely used for cervical lesions, freezing abnormal tissue with liquid nitrogen or carbon dioxide. While effective, it can cause discomfort, scarring, and recurrence. Cryoablation, however, represents a major breakthrough, particularly in Sydney, where MRI-guided cryoablation is used to freeze deep internal tumors such as those in the spine, liver, kidney, and prostate. This minimally invasive approach preserves organ function and reduces surgical risks.

Common Cancers Treated With Cryoablation

Additional Uses

Focused Ultrasound: Sound Waves Against Cancer

Focused ultrasound is one of the most exciting modern advances in frequency-based medicine. It uses concentrated sound waves to target tumors deep inside the body without incisions. This breakthrough is particularly important for glioblastoma, one of the most aggressive and treatment-resistant cancers.

Beyond the brain, focused ultrasound is being tested for prostate cancer, uterine fibroids, and liver tumors. Its non-invasive nature makes it appealing for patients who cannot undergo surgery. Unlike cryoablation, which requires needle insertion, focused ultrasound delivers energy externally, guided by imaging. This precision reduces risks and recovery time. While still experimental in many applications, its potential to revolutionize oncology is immense, especially as imaging and targeting technologies improve.

Raymond Rife’s Technique: The Visionary Beginning

Raymond Rife’s work in the 1930s laid the conceptual foundation for frequency-based medicine. He believed that every microorganism had a “mortal oscillatory rate”—a frequency that could destroy it without harming surrounding tissue. He built frequency-generating devices, known as Rife machines, and succeeded in killing pathogens and even cancer cells.

Although his work was never validated in controlled clinical trials due to lobbying by powerful people and entities, Rife’s vision anticipated the modern use of frequencies in medicine. Today, PDT uses light frequencies, focused ultrasound uses sound waves, and cryoablation uses thermal energy—all echoing Rife’s principle that energy can selectively target disease. Rife machines remain popular in alternative health circles and now people are ensuring its scientific proof. His pioneering ideas continue to inspire exploration into frequency-based therapies.

Frequency Healthcare And Med Beds

Frequency Healthcare and med beds represent novel and intriguing extensions of energy medicine. Frequency Healthcare emphasizes vibrational resonance, sound waves, or electromagnetic fields to restore cellular harmony. Med beds are often described as futuristic devices that use plasma energy or advanced frequencies to regenerate tissues, repair DNA, and even reverse aging.

Unlike PDT, cryoablation, or ultrasound, these approaches currently lack clinical validation but work is going on in this direction. However, they are gaining popularity among patients averse to chemotherapy and radiation poisons. The appeal lies in their promise of non-invasive, painless, and regenerative healing. Patients are drawn to the idea of treatments that not only destroy cancer but also restore the body holistically. Rife’s Technique, Frequency Healthcare, and Med Beds have tremendous potential to cure cancer and ensure a holistic and wholesome cancer treatment experience that toxic and barbaric practices like chemotherapy, radiation and needle biopsy can never achieve.

Comparative Analysis Of Cancer Therapies

Cancer-Type Specific Therapy Comparison

Brain Cancer

Cervical Cancer (HPV-related)

Skin Cancer

Liver Cancer

Historical Timeline Of Frequency-Based Medicine

Success Stories Of Frequency-Based Medicine

The timeline of frequency-based medicine is marked by several notable success stories. Photodynamic Therapy (PDT) has eradicated HPV infections in clinical trials and is widely used for superficial cancers, offering a safe, non-invasive alternative to surgery or chemotherapy. Cryoablation has transformed treatment for deep internal tumors, particularly in the liver, kidney, and prostate, by freezing cancerous tissue with MRI-guided precision. Focused ultrasound has opened new possibilities in brain cancer care, safely disrupting the blood-brain barrier to improve drug delivery in glioblastoma patients.

These successes highlight how frequency-based approaches—light, sound, and cold—have moved from speculative ideas into validated medical practice. While suppressed methods like Rife machines and med beds are yet to be accepted at mass scale, their popularity reflects a growing demand for treatments that heal without the harsh side effects of chemotherapy. The validated therapies demonstrate that energy medicine is not only possible but already transforming oncology, with the potential to expand further into systemic and regenerative care in the future.

Conclusion

The evolution of cancer care shows a clear trajectory toward energy-based, non-invasive therapies. PDT has proven highly effective for HPV-related and superficial cancers, cryoablation excels in deep internal tumors, and focused ultrasound is revolutionizing brain cancer treatment. Raymond Rife’s visionary ideas laid the conceptual foundation, while Frequency Healthcare and med beds represent novel and aspirational extensions of this paradigm.

No single therapy cures all cancers, except Frequency Healthcare and Rife Machine. Chemotherapy has become redundant for cancer treatment and its toxicity and fatalities drive patients to seek safer alternatives. PDT, cryoablation, and ultrasound each fill critical roles depending on cancer type and stage, while Rife-inspired and med bed concepts symbolize the hope for universal, painless cures. The most realistic future lies in integration: combining validated therapies with emerging technologies to create a comprehensive, patient-centered approach. This integrated model could one day fulfill the promise of frequency-based medicine—treating cancer effectively while preserving quality of life.

India’s HPV vaccination story is one of controversy, stagnation, and cautious progress. In 2010, pilot projects in Andhra Pradesh and Gujarat, conducted with international partners, were abruptly halted after shameful cases of unethical consent procedures and reports of deaths among participants. As a result the public trust collapsed, and HPV vaccination rates dropped to virtually zero nationwide. Surprisingly, forced HPV vaccination without consent of parents is still going on in March 2026 and India has not learnt any lesson from its shameful acts of the past.

For instance, on March 11, 2026, five teenage girls fell ill after receiving the HPV Shots in Barkari Jigniya village of Madhya Pradesh’s Gwalior district. According to family members, the girls were taken for vaccination by an anganwadi worker without consent of their parents. Allegedly, the girls were coerced into submission by peddling false promises and lie that the girls would receive ₹50,000 and assistance for their marriage if they signed a form before vaccination. After returning home, the girls began complaining of vomiting, dizziness, and fever, prompting their families to admit them to the Civil Hospital in Dabra for treatment. Family members are furious that they were not informed at all regarding the HPV Death Shots, raising significant ethical, healthcare and Human Rights concerns about forceful poisoning and Depopulation Agenda.

Recent incidents further fuel concerns about HPV Shots safety. HPV Shots have serious side effects and this includes Death too. A complete list of all side effects of HPV Shots is now available for global stakeholders and that is why Smart Girls Have Rejected HPV Shots In India. A cursory look at these deadly side effects would ensure that you would never even like to see HPV Shots any more in your lifetime. Another scientific, well-researched and legitimate piece of article is titled Sterilisation, Infertility, and Cancer Causing Effects of HPV Shots. It is a real eye opener and exposes how the dangerous stats and info about infertility and sterilisation in India due to Death Shots has been suppressed since 2016 under Modi govt.

Between 2010 and 2015, HPV vaccination remained absent from the national immunisation programme. Uptake was negligible, limited to private healthcare settings where costs were prohibitive. National coverage during this period was realistically well below 1%, despite occasional claims of higher figures. By 2020, a few states — Delhi, Punjab, and Sikkim — introduced HPV vaccination programs. These were small, localized initiatives, covering tens of thousands of girls at most. While some reports suggested “3–5% coverage,” this figure reflected state‑level penetration, not national reality. When extrapolated across India’s adolescent population, true national coverage was closer to 0.5–1%. From 2021 to 2025, uptake remained stagnant, with no nationwide rollout and limited private‑sector access.

The turning point came in February 2026, when the government launched a nationwide HPV vaccination campaign under the Universal Immunisation Programme. The drive targeted 1.15 crore (11.5 million) adolescent girls annually, adopted the WHO‑endorsed single‑dose norm, and used Gardasil‑4. This was heralded as a landmark public health achievement. Yet the numbers tell a more sobering story. By March 25, 2026 — 25 days after launch — only 3 lakh (300,000) girls had been claimed to be vaccinated. This represents 2.6% of the target population, while 28% of the campaign’s 90‑day duration had already elapsed. Earlier government and media accounts exaggerated progress, loosely describing “millions vaccinated,” when the govt claimed figure was hundreds of thousands. The mismatch between time elapsed and coverage achieved highlights the mass failure of HPV Death Shots campaign of Modi Govt in 2026.

Corrected Timeline Of HPV Vaccination Coverage In India (2010–2026)

Manipulation Of Data And Reporting Systems

India has a long history of manipulating and selectively presenting data to bolster official narratives, particularly under the Modi government. This tendency has been documented in multiple domains. For example, the article titled infertility and fertility decline in India highlights how demographic and reproductive health statistics have been massaged to present a more favorable picture of national progress. India’s fertility decline may be systematically understated to acknowledge the speed of demographic change. India would face aging challenges, shrinking labor supply, and economic restructuring much sooner than expected.

Importantly, exposes and independent estimates suggest India’s fertility decline is sharper than official figures indicate, with real rates possibly closer to 1.7 than the reported 1.9. This discrepancy highlights the urgent need for transparent demographic data and accurate reporting, as underestimating the pace of fertility decline could leave policymakers unprepared for the challenges of an aging population, shrinking labor force, and economic restructuring.

This pattern of exaggeration and selective reporting mirrors what we see in HPV vaccination coverage, where modest early achievements are inflated into claims of “millions vaccinated.”

Similarly, the article titled analysis of Global HPV Vaccination Coverage in Transition exposes the complexity of WHO’s reporting system and how governments exploit it. The shift to a single‑dose schedule expanded access, simplified logistics, and enabled more efficient use of vaccine supply. However, it also rendered the traditional “at least one dose” metric increasingly ambiguous. Without distinguishing between full and partial vaccination or accounting for national schedule choices, global indicators no longer accurately reflect true protection levels.

The continued use of a single undifferentiated metric risks underestimating progress in countries that have adopted the single‑dose schedule and overestimating protection in countries that continue to require two doses. It also obscures the distribution of immunity gaps, complicating efforts to target resources effectively.

India’s official narrative benefits from these ambiguities, presenting inflated numbers that appear impressive but do not reflect actual immunisation rates. By claiming “millions vaccinated” while verified figures show only 300,000 doses administered in 25 days, India exemplifies how reporting systems can be manipulated to project success while masking shortfalls.

Analytical Projection For 2026

At the current pace (~12,000 claimed vaccinations per day), India will vaccinate 1.1–1.2 million girls in 90 days, or 10–11% of the target. Even with acceleration to 40,000 per day, coverage would reach only ~31%. Only at an ambitious pace of 100,000 per day could India approach ~78% of the target. This is impossible to achieve as even the 10% target is unachievable as 99% of targeted girls are not taking HPV Shots in 2026.

In fact, due to the the “Lies Model” of Modi govt, it is even difficult to believe that 3 lakh girls have already taken these HPV Death Shots.

Stay away and stay protected and do not fall for the lies of Modi govt once more. You have already been fooled by the COVID-19 Plandemic and COVID-19 Death Shots of Modi govt.

Conclusion

India’s adoption of the single‑dose HPV vaccination norm is a desperate step and the reality of coverage is far less impressive than official claims suggest. From negligible uptake after the 2010–2012 controversy to only claimed but suspected 300,000 girls vaccinated in the first month of 2026, progress remains modest. The government’s narrative of “millions vaccinated” exaggerates early achievements, masking the fact that the campaign is behind schedule. Unless the pace accelerates dramatically, India will end its first 90‑day campaign with 10–12% coverage, far short of the ambitious 1.15 crore target. But even 2% target is next to impossible if we take into account actual vaccination stats and truth and not typical lies of Modi govt.

The evidence from infertility reporting and WHO’s HPV data systems shows that India’s exaggeration is not an isolated case but part of a broader pattern of statistical manipulation. Transparent reporting and independent verification are essential if India is to truly lead in cervical cancer prevention rather than merely claim success.

Introduction

The 21st century has witnessed a dramatic transformation in global fertility patterns. Since 2010, fertility rates have declined across most regions, with many nations now falling below the replacement level of 2.1 births per woman. Death Shots and Biological And Chemical Experiments by State on its own citizens are two main causes of infertility and sterilisation among global population.

This is part of the larger goal of Depopulation Agenda and sinister Population Control where Genocidal Maniacs and Pharmaceutical Cartel are the main beneficiaries. Now In Vitro Fertilisation (IVF) segment has also joined this “Macabre Race.” COVID-19 Plandemic and the COVID-19 Death Shots cleared this picture once for all and that is why 99% of girls in India have rejected the latest HPV Death Shots in March 2026.

This demographic shift has profound implications for population stability, labor supply, and economic growth. Assisted reproductive technologies (ART), particularly In Vitro Fertilisation (IVF), have emerged as vital tools to address infertility and declining birth rates.

India, once characterized by high fertility, has now joined the ranks of countries below replacement level. Yet, debates and exposes have surfaced, suggesting that India’s fertility decline may be even sharper than official figures indicate, raising concerns about data transparency and the urgency of policy responses. This article examines global and Indian fertility trends from 2000 to March 25, 2026, explores IVF’s role, and integrates critical perspectives on India’s demographic data.

Global Fertility Decline

The global fertility rate has dropped from 2.6 births per woman in 2000 to about 2.3 in 2023, with several countries experiencing ultra-low fertility. Nations such as South Korea, Japan, Italy, Spain, and Germany are among the hardest hit, with rates well below replacement levels. The consequences of failing to meet replacement rates by 2030 include shrinking labor forces, aging populations, and economic stagnation.

Table 1: Top 10 Countries With Major Fertility Declines (2000–2026)

India’s Fertility Trends And Exposes

India has seen a steady decline from 2.6 in 2010 to 1.93 in 2026, now below replacement level, due to Death Shots and Human Experimentation. However, several exposes and critical studies have argued that India’s fertility rate may be lower than officially claimed.

The Hindu (2025) questioned whether India’s reported fertility rate of 1.9 accurately reflects reality, pointing to a gap between real and calculated Total Fertility Rate (TFR). The Center for the Advanced Study of India (CASI) similarly argued that India’s demographic shifts are not adequately documented, with official statistics lagging behind actual changes. A technical study published on Research Square (2025) used machine learning to analyze NFHS and Census data, finding that states such as Andhra Pradesh, Kerala, and Tamil Nadu had already reached fertility rates well below 1.8. This suggests India’s national average could be closer to 1.7, rather than the reported 1.9.

These exposes reveal a consistent theme: India’s fertility decline may be systematically understated, whether due to survey limitations, outdated methodologies, or political reluctance to acknowledge the speed of demographic change. In short, India could face aging challenges, shrinking labor supply, and economic restructuring much sooner than expected.

Table 2: India’s Fertility Rate (2010–2026)

IVF As A Response To Infertility

Globally, IVF has grown from ~200,000 cycles in 2000 to over 3 million cycles annually by 2025, resulting in millions of births. IVF demand correlates with declining fertility and rising infertility due to lifestyle and medical conditions.

Table 3: Global IVF Demand And Births (2000–2026)

IVF In India

India’s IVF industry has expanded rapidly, driven by Death Shots and Human Experimentation. By 2026, IVF is mainstream, supported by AI-driven embryo selection and personalized fertility care.

Table 4: IVF In India (2010–2026)

Conclusion

Since 2010, sterilisation and declining fertility rates have become defining demographic challenges worldwide due to Death Shots and Human Experimentation. IVF has emerged as a money making solution, with exponential growth in demand and births. Yet, IVF alone cannot offset demographic decline; comprehensive policies addressing family support, healthcare, and social incentives are essential to stabilize populations by 2030. Above all, people should be aware of the Human Experiments and say no to all Death Shots.

India’s trajectory shows both promise and risk. While IVF provides hope to millions, the nation must prepare for the socioeconomic consequences of Death Shots based sterilisation and sustained low fertility. Importantly, exposes and independent estimates suggest India’s fertility decline is sharper than official figures indicate, with real rates possibly closer to 1.7 than the reported 1.9. This discrepancy highlights the urgent need for transparent demographic data and accurate reporting, as underestimating the pace of fertility decline could leave policymakers unprepared for the challenges of an aging population, shrinking labor force, and economic restructuring.

The global lesson is clear: fertility decline is not just a medical or demographic issue, but a strategic challenge for societies and economies. IVF and other assisted reproductive technologies will continue to play a crucial role, but they must be complemented by robust social policies, family support systems, and proactive planning. For India, acknowledging the true extent of fertility decline due to Death Shots is the first step toward crafting effective responses that safeguard both its demographic future and economic resilience.

Introduction

Bees are among the most vital organisms on Earth, serving as primary pollinators for countless plant species and underpinning global food security. Their ecological role extends far beyond agriculture, as they sustain biodiversity by enabling the reproduction of flowering plants, which in turn support entire ecosystems. Yet, bee populations worldwide are in decline, and this crisis is not the result of natural cycles alone. It is driven by human activities—industrial agriculture, policy decisions that prioritize profit over sustainability, and environmental degradation. This “silent war” against bees is insidious, unfolding gradually and often unnoticed, but its consequences are profound. Without bees, the stability of ecosystems and the availability of diverse food crops are jeopardized, threatening both ecological balance and human survival.

Pesticides And Agrochemical Dependence

The reliance on pesticides, particularly neonicotinoids, epitomizes the conflict between short-term agricultural productivity and long-term ecological health. These chemicals are systemic, meaning they permeate plant tissues and contaminate nectar and pollen. Bees exposed to them suffer impaired navigation, reduced foraging efficiency, weakened immunity, and increased vulnerability to pathogens. Despite extensive scientific evidence linking pesticides to colony collapse, many governments continue to permit their use under pressure from agrochemical corporations. This reflects a policy environment where economic interests override ecological responsibility, perpetuating conditions that undermine pollinator populations.

Genetically Modified Crops And Pathogen Synergy

Genetically modified crops, especially Bt varieties, are promoted as innovations to enhance yield and reduce pest damage. However, research indicates that Bt pollen can interact with pathogens such as Nosema ceranae, intensifying infections and increasing bee mortality. The expansion of GMO agriculture, often supported by permissive regulatory frameworks, introduces new ecological stressors that destabilize pollinator health. These crops are emblematic of a profit-driven agricultural model that prioritizes productivity while neglecting the unintended consequences for pollinators and ecosystems.

Industrial Pollutants And Environmental Contamination

Industrial pollutants represent another dimension of the silent war. Heavy metals, microplastics, and airborne contaminants infiltrate bee tissues, disrupting physiological processes and reducing colony resilience. These pollutants originate from manufacturing, mining, and urban expansion—sectors frequently shielded by lenient environmental regulations. The prioritization of industrial growth over ecological protection has created toxic landscapes where bees struggle to survive. Pollution is not merely a local issue; it is a global phenomenon that compounds other stressors and accelerates bee decline.

Deforestation, Monoculture, And Habitat Loss

Habitat destruction through deforestation and the spread of monoculture farming deprives bees of diverse floral resources. Nutritional diversity is critical for colony health, and its absence weakens resilience against disease and environmental stress. Global demand for commodities such as soy, palm oil, and timber drives large-scale habitat loss, often sanctioned by government policies that prioritize economic development over conservation. Monocultures, while efficient for industrial agriculture, create ecological deserts for pollinators, further intensifying the crisis.

Diseases And Pathogenic Pressures

The weakening of bee colonies by strange diseases and parasites has become a major nuisance and we need more scientific research in this field to find the cause and cures. Viral pathogens such as Deformed Wing Virus (DWV), Acute Bee Paralysis Virus (ABPV), and Israeli Acute Paralysis Virus (IAPV), often vectored by Varroa destructor mites, cause deformities, paralysis, and rapid colony collapse. Bacterial infections like American Foulbrood (Paenibacillus larvae) and European Foulbrood (Melissococcus plutonius) destroy brood and spread quickly within hives. Fungal diseases, including Nosema apis and Nosema ceranae, compromise digestive function and energy metabolism, while Chalkbrood (Ascosphaera apis) weakens colony productivity. Parasitic infestations, particularly Varroa mites and tracheal mites, amplify the impact of these pathogens, creating cascading colony failures. These illnesses are not isolated phenomena but symptoms of systemic ecological stress.

Policy Decisions And Economic Drivers

The decline of bees cannot be understood without examining the policy decisions and economic drivers that sustain harmful practices. Subsidies for industrial agriculture, lenient pesticide regulations, and permissive GMO policies reflect governance models that externalize ecological costs. Agricultural systems are framed as profit-maximizing enterprises, marginalizing pollinator health and treating bees as expendable. Industrial expansion, often justified by economic growth, disregards ecological consequences. This policy environment institutionalizes practices that perpetuate the silent war against bees, making reform essential to reversing the crisis.

Measures To Protect And Increase Bee Populations

Protecting bees requires integrated strategies that address ecological, agricultural, and policy dimensions. Habitat restoration through the planting of native, diverse flowering species provides year-round nutrition. Reducing pesticide use and adopting integrated pest management strategies can minimize chemical stress. Pollution control policies must target industries that contribute to environmental contamination, while GMO crops should undergo rigorous ecological risk assessments. Disease and parasite management, including biological control methods for Varroa destructor and breeding programs for disease-resistant strains, can strengthen colony resilience. Policy reforms are essential: governments must introduce pollinator protection laws, restrict harmful practices, and provide subsidies for sustainable farming. Community-level initiatives, such as awareness campaigns, citizen science projects, and urban pollinator gardens, can complement global governance efforts.

Conclusion

The global decline of bees represents a convergence of ecological vulnerability and human economic priorities. Pesticides, GMOs, pollutants, deforestation, chemtrails and geo-engineering, vaccinated plants and foods, and pathogens interact to weaken colonies and amplify disease spread, while policy decisions and profit-driven practices sustain these pressures. This crisis is not merely about pollinators—it is about the stability of ecosystems and the security of human food systems. Bees are indicators of ecological health, and their decline signals systemic imbalance. Addressing this crisis requires a paradigm shift: from short-term economic gains to long-term ecological stewardship. Governments must enact strong regulatory frameworks, industries must adopt sustainable practices, and communities must engage in conservation efforts. Only through coordinated global action can humanity reverse the silent war against bees, ensuring the survival of pollinators and safeguarding the ecological foundations upon which life depends.

Abstract

Between 2020 and 2026, global HPV vaccination programs underwent a fundamental transformation as countries transitioned from a two‑dose to a single‑dose schedule. This shift altered the meaning of the widely used “at least one dose” coverage indicator, complicating interpretation of global progress. This manuscript examines global HPV vaccination trends during this period, contextualizes the WHO’s endorsement of the single‑dose schedule, and analyzes how evolving national policies reshaped the significance of first‑dose coverage. The findings highlight the need for updated global monitoring frameworks that distinguish between full and partial vaccination in an era where one dose increasingly represents complete protection.

Introduction

Human papillomavirus (HPV) vaccination is a controversial vaccine with many serious side effects and even possibility of death. It is of utmost importance that all details about HPV Death Shots are properly recorded to their last detail so that Absolute Liability can be fixed upon those pushing it. It is now globally accepted that Death Shots Are Absolute Liability Medical Offenses and govts would be soon forced to accept this fact and enact it into enforceable laws. to achieve that we not only need a foolproof adverse side effects and deaths reporting system for each country but we also must have reliable data and stats regarding the same. Unfortunately, not even 1% adverse and severe side effects and deaths are reported globally, giving a false sense of security that Death Shots are safe and secure. The COVID-19 Plandemic and COVID-19 Death Shots proved this to be absolutely nonsense and it is now clear that Death Shots are unsafe, ineffective and are causing deaths globally.

Historically, most countries implemented a two‑dose schedule for adolescent girls, and global coverage was reported using the proportion who received at least one dose. This metric was straightforward when one dose universally represented partial vaccination. However, between 2020 and 2026, the global HPV vaccination landscape changed dramatically as scientific evidence and policy shifts led to widespread adoption of a single‑dose schedule. As a result, the meaning of “one dose” diverged across countries, rendering the traditional indicator increasingly ambiguous.

Global Coverage Trends Before And After The Policy Shift

In 2020, global first‑dose HPV vaccination coverage stood at 16%. Nearly all countries used a two‑dose schedule, and a single dose indicated only partial vaccination. Coverage remained stagnant through 2021 and into early 2022, hovering around 16–17%. This stagnation reflected persistent challenges in delivering multi‑dose adolescent vaccines, including logistical constraints, school disruptions, and the broader impact of the COVID‑19 pandemic on routine immunization systems.

A pivotal change occurred in 2022. In April, the WHO Strategic Advisory Group of Experts (SAGE) endorsed a single‑dose HPV vaccination schedule as an effective alternative to the two‑dose regimen, with the formal WHO position paper published in December 2022. This endorsement catalyzed a global transition toward simplified delivery.

To contextualize these shifts, the following table summarizes global HPV vaccination coverage and schedule evolution from 2020 to 2026:

Global HPV Vaccination Context, 2020–2026

Adoption Of The Single‑Dose Schedule And Its Implications

Countries began adopting the single‑dose schedule in 2023 and 2024, but the pace of transition varied widely. Some countries moved rapidly to implement the new schedule, others retained the two‑dose regimen, and some adopted mixed approaches depending on age group or epidemiological context. As a result, the global first‑dose coverage figure of 21% in 2024 no longer represented a uniform vaccination status. In countries using the new schedule, one dose indicated full vaccination; in countries retaining the two‑dose schedule, one dose still indicated partial vaccination.

This divergence created a situation in which a single global indicator blended fundamentally different immunization outcomes. The complexity was further amplified by countries that retroactively reclassified earlier one‑dose recipients as fully vaccinated once they adopted the single‑dose schedule. Consequently, the global first‑dose metric encompassed individuals fully vaccinated with one dose, individuals partially vaccinated with one dose, individuals who completed two doses, and individuals whose earlier single dose was later reclassified as complete.

Global Landscape In 2025–2026

By 2025 and 2026, the global landscape had shifted decisively toward the single‑dose approach. Although no single global first‑dose percentage was published for these years, coverage continued to rise due to new national introductions, improved supply, and simplified delivery. By 2026, 164 countries had introduced HPV vaccination nationally or subnationally, and 89 countries—more than half of all HPV‑vaccinating countries—had adopted a single‑dose schedule. This marked the first time that the single‑dose approach represented the global majority.

Regional data showed particularly strong gains in Africa, where first‑dose coverage increased from 17% in 2020 to 28% in 2024, with further increases expected as more countries transitioned to the simplified schedule.

Interpretation Challenges And The Need For Updated Metrics

The shift to a single‑dose schedule expanded access, simplified logistics, and enabled more efficient use of vaccine supply. However, it also rendered the traditional “at least one dose” metric increasingly ambiguous. Without distinguishing between full and partial vaccination or accounting for national schedule choices, global indicators no longer accurately reflect true protection levels.

The continued use of a single undifferentiated metric risks underestimating progress in countries that have adopted the single‑dose schedule and overestimating protection in countries that continue to require two doses. It also obscures the distribution of immunity gaps, complicating efforts to target resources effectively.

Conclusion

The period from 2020 to 2026 has proved that people are now aware of the futility and dangers of HPV Death Shots. That is why all sorts of manipulations, data fudging, dubious methods, etc have been introduced globally. Despite the introduction of single shot system, there is just a meager increase of 5% from 2020 to 2024. This also includes those shots that are part of the second shots of the two shots system. Effectively, people have rejected HPV Death Shots after the COVID-19 Plandemic and COVID-19 Death Shots. As of 25th March 2026, 99% of global people and Indians have rejected HPV Death Shots as people are not taking them at all in March 2026.

India’s national rollout reignited debate in New Delhi, with renewed calls for fertility-specific monitoring.The Techno-Legal Framework to Prevent Global Vaccines Genocide (TLFPGVG) has not only cautioned against deadly and severe side effects of HPV Death Shots but it has also raised serious concerns about the “Infertility And Sterilisation Effects Of HPV Death Shots.” The TLFPGVG has also outlined methods to deal with Vaccines Genocide Cult Of India (VGCI).

The TLFPGVG has also declared that Indians now demand “Absolute Liability For Medical Offenses” and consider “Death Shots As Absolute Liability Offenses.” Sovereign P4LO has now also declared that Unacceptable Human Harm Theory (UHHT) would now be implemented in India by using the OLA Theory To Annul Legal Immunity For Death Shots.

So as of 25th March 2026, HPV Death Shots have been totally rejected in India by Sovereign P4LO, The TLFPGVG, UHHT, and OLA Theory. Indians need not to follow any direction of any institution or authority in this regard.